Track market-moving stories before they get noisy

Axxcess Wealth Management LLC lessened its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 67.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 30,628 shares of the healthcare product maker’s stock after selling 64,579 shares during the period. Axxcess Wealth Management LLC’s holdings in Abbott Laboratories were worth $3,027,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Bank of America Corp DE purchased a new stake in shares of Abbott Laboratories in the second quarter valued at approximately $1,603,607,000. Legal & General Group Plc bought a new position in Abbott Laboratories in the second quarter worth approximately $1,082,524,000. Flossbach Von Storch SE purchased a new position in Abbott Laboratories during the 2nd quarter worth $902,938,000. Jupiter Topco LLC purchased a new position in Abbott Laboratories during the 2nd quarter worth $732,788,000. Finally, BlackRock Inc. raised its position in Abbott Laboratories by 4.6% during the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock valued at $13,843,610,000 after purchasing an additional 6,769,518 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes Several equities research analysts have weighed in on the company. Weiss Ratings upgraded Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, September 18th. Citigroup cut their price target on Abbott Laboratories from $125.00 to $122.00 and set a “buy” rating on the stock in a research note on Thursday. Royal Bank Of Canada decreased their price objective on Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Thursday. Wells Fargo & Company upped their price objective on shares of Abbott Laboratories from $112.00 to $119.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, BTIG Research cut their target price on shares of Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating on the stock in a research report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $118.32.

View Our Latest Stock Analysis on ABT Abbott Laboratories Trading Up 2.1% Shares of NYSE ABT opened at $102.64 on Friday. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $132.02. The business has a fifty day moving average price of $105.30 and a 200 day moving average price of $98.28. The stock has a market capitalization of $177.61 billion, a P/E ratio of 18.68, a price-to-earnings-growth ratio of 1.86 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.42. The company had revenue of $13.01 billion for the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The firm’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.30 earnings per share. Equities research analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. Abbott Laboratories’s payout ratio is presently 81.55%.

Abbott Laboratories News Roundup Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Abbott reported third-quarter adjusted EPS of $1.42, in line with the main consensus estimate, and revenue of $13.01 billion, slightly above the $12.99 billion estimate. Reported sales rose 14.5% year over year, while comparable sales increased 7%. Abbott third-quarter results Positive Sentiment: Abbott reaffirmed its full-year adjusted EPS guidance, and analysts continue to see upside. Wells Fargo raised its price target to $119, while Robert W. Baird raised its target to $123. Citigroup, RBC, JPMorgan, TD Cowen and BTIG lowered targets but retained bullish ratings, including “buy,” “outperform” or “overweight.” Positive Sentiment: The company received European approval for its Cologuard Plus colorectal-cancer screening test, expanding the potential market for its diagnostics portfolio. Abbott Cologuard Plus European approval Neutral Sentiment: Abbott plans a tax-free separation of its approximately $8.5 billion Nutrition business into an independent, publicly traded company by the end of 2027. Management says the move could give both businesses more focused investment strategies, but investors face execution, allocation and valuation uncertainty during the transition. Abbott Nutrition separation announcement Negative Sentiment: Abbott reduced its 2026 sales-growth outlook, citing pressure from diabetes-related pricing and weakness in parts of its electrophysiology and medical-device businesses. This softer outlook overshadowed the quarterly revenue performance and led several analysts to trim price targets. Abbott lowers 2026 sales forecast Negative Sentiment: India’s food regulator issued a notice involving infant-formula claims related to Nestlé India and Abbott, creating a limited regulatory overhang for Abbott’s Nutrition operations. India infant-formula regulatory notice Abbott Laboratories Company Profile (Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

Further Reading Five stocks we like better than Abbott Laboratories Is Texas Instruments Setting Up for Its Next Big Breakout? Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was Tesla’s Flying-Car Hype Hits an Earnings Reality Check Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent Third-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42 Expands portfolio with key new product approvals , /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2026.

Third-quarter sales increased 14.5 percent on a reported basis and 7.0 percent on a comparable basis. Third-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42, which excludes specified items. Abbott projects full-year 2026 comparable sales growth to be approximately 6.0 percent1. Abbott reaffirms the midpoint of previously provided full-year 2026 adjusted diluted EPS guidance range and tightens the range to $5.50 to $5.55. In August, Abbott announced U.S. Food and Drug Administration (FDA) approval for Libre® Duo, the world's first dual glucose-ketone biowearable sensor. By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the management of diabetes by detecting rising ketone levels, which can lead to diabetic ketoacidosis, a serious health condition for people with diabetes. In August, Abbott announced that the company received CE Mark for its Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce the risk of stroke in patients with atrial fibrillation (AFib). In August, Abbott announced the launch of Similac® 360 Total Care® Made With Whole Milk —  the first and only commercially sterile, ready-to-feed liquid infant formula made with whole milk in the United States. In September, Abbott announced FDA approval for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, designed to deliver both pulsed field ablation (PFA) and radiofrequency (RF) energy to treat patients battling atrial fibrillation. In September, Abbott launched SimpleScreen™ CRC, an FDA-approved, blood-based colorectal cancer screening test for adults age 45 and older who are at average risk for the disease. "Abbott delivered strong third-quarter results, reflecting balanced growth across our portfolio," said Robert B. Ford, chairman and chief executive officer, Abbott. "With strong performance across multiple businesses and a robust pipeline of innovation, we are well-positioned to deliver sustainable growth in the years ahead."

THIRD-QUARTER BUSINESS OVERVIEW

Comparable sales growth:
Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. 

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total Company

Nutrition

Diagnostics

Established
Pharmaceuticals

Medical Devices

U.S.

5,504

958

1,853

—

2,687

International

7,509

1,304

1,452

1,614

3,139

Total reported

13,013

2,262

3,305

1,614

5,826

% Change vs. 3Q25

U.S.

28.0

7.9

109.2

n/a

6.6

International

6.2

3.1

6.2

6.8

7.2

Total reported

14.5

5.1

46.7

6.8

6.9

Total reported excl. foreign exchange impact

14.8

4.9

46.6

8.4

7.4

Comparable sales growth

7.0

4.9

6.4

8.4

7.8

    U.S.

7.9

7.9

8.4

n/a

7.6

    International

6.4

2.8

4.0

8.4

8.0

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total Company

Nutrition

Diagnostics

Established
Pharmaceuticals

Medical Devices

U.S.

14,994

2,673

4,418

—

7,890

International

21,776

3,750

4,159

4,539

9,328

Total reported

36,770

6,423

8,577

4,539

17,218

% Change vs. 9M25

U.S.

17.7

(4.5)

72.0

n/a

7.1

International

8.2

1.1

6.3

9.3

11.7

Total reported

11.9

(1.3)

32.4

9.3

9.6

Total reported excl. foreign exchange impact

10.5

(2.1)

30.8

8.7

7.8

Comparable sales growth

5.2

(2.1)

3.8

8.7

8.2

    U.S.

4.7

(4.5)

4.9

n/a

8.1

    International

5.7

(0.3)

2.4

8.7

8.3

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Nutrition

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total

Pediatric

Adult

U.S.

958

577

381

International

1,304

486

818

Total reported

2,262

1,063

1,199

% Change vs. 3Q25

U.S.

7.9

11.0

3.5

International

3.1

6.4

1.3

Total reported

5.1

8.8

2.0

Total reported excl. foreign exchange impact

4.9

8.7

1.8

Comparable sales growth

4.9

8.7

1.8

    U.S.

7.9

11.0

3.5

    International

2.8

6.0

1.0

Worldwide Nutrition sales increased 5.1 percent on a reported basis and 4.9 percent on a comparable basis in the third quarter.

Worldwide Nutrition results were driven by broad-based growth across the portfolio, including sales growth of nearly 9.0 percent in Worldwide Pediatric.

On a sequential basis, Worldwide Nutrition sales increased $118 million compared to the second quarter of 2026.

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total

Pediatric

Adult

U.S.

2,673

1,613

1,060

International

3,750

1,428

2,322

Total reported

6,423

3,041

3,382

% Change vs. 9M25

U.S.

(4.5)

(4.8)

(4.0)

International

1.1

3.7

(0.5)

Total reported

(1.3)

(1.0)

(1.6)

Total reported excl. foreign exchange impact

(2.1)

(1.6)

(2.6)

Comparable sales growth

(2.1)

(1.6)

(2.6)

    U.S.

(4.5)

(4.8)

(4.0)

    International

(0.3)

2.4

(2.0)

Diagnostics*

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total

Core Laboratory

Cancer Diagnostics

Rapid/Molecular
Diagnostics

U.S.

1,853

389

938

526

International

1,452

1,049

30

373

Total reported

3,305

1,438

968

899

% Change vs. 3Q25

U.S.

109.2

6.3

n/a

1.1

International

6.2

5.1

n/a

1.0

Total reported

46.7

5.4

n/a

1.1

Total reported excl. foreign exchange impact

46.6

5.4

n/a

0.9

Comparable sales growth

6.4

5.4

13.8

0.9

    U.S.

8.4

6.3

13.9

1.1

    International

4.0

5.1

12.1

0.7

Worldwide Diagnostics sales increased 46.7 percent on a reported basis and 6.4 percent on a comparable basis in the third quarter.

Worldwide Core Laboratory Diagnostics results were driven by balanced growth across major geographic regions including the U.S., Europe, Japan, and Latin America.

Cancer Diagnostics results were driven by growth of Cologuard® and also reflect contributions to growth from the precision oncology and international businesses.

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total

Core Laboratory

Cancer Diagnostics

Rapid/Molecular
Diagnostics

U.S.

4,418

1,113

1,921

1,384

International

4,159

3,015

62

1,082

Total reported

8,577

4,128

1,983

2,466

% Change vs. 9M25

U.S.

72.0

6.1

n/a

(8.9)

International

6.3

5.8

n/a

1.9

Total reported

32.4

5.9

n/a

(4.5)

Total reported excl. foreign exchange impact

30.8

4.0

n/a

(5.4)

Comparable sales growth

3.8

4.0

13.5

(5.4)

    U.S.

4.9

6.1

13.5

(8.9)

    International

2.4

3.2

15.0

(0.4)

*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott's Cancer Diagnostics business.

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Established Pharmaceuticals

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total

Key Emerging
Markets

Other

U.S.

—

—

—

International

1,614

1,195

419

Total reported

1,614

1,195

419

% Change vs. 3Q25

U.S.

n/a

n/a

n/a

International

6.8

9.0

1.1

Total reported

6.8

9.0

1.1

Total reported excl. foreign exchange impact

8.4

10.9

1.6

Comparable sales growth

8.4

10.9

1.6

    U.S.

n/a

n/a

n/a

    International

8.4

10.9

1.6

Established Pharmaceuticals sales increased 6.8 percent on a reported basis and 8.4 percent on a comparable basis in the third quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 9.0 percent on a reported basis and 10.9 percent on a comparable basis, led by double-digit growth in India and several markets across the Latin America and Asia Pacific regions.

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total

Key Emerging
Markets

Other

U.S.

—

—

—

International

4,539

3,448

1,091

Total reported

4,539

3,448

1,091

% Change vs. 9M25

U.S.

n/a

n/a

n/a

International

9.3

10.5

5.6

Total reported

9.3

10.5

5.6

Total reported excl. foreign exchange impact

8.7

10.4

3.6

Comparable sales growth

8.7

10.4

3.6

    U.S.

n/a

n/a

n/a

    International

8.7

10.4

3.6

Medical Devices

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total

Rhythm
Management

Electro-
physiology*

Heart
Failure

Vascular

Structural
Heart*

Neuro-
modulation

Diabetes
Care

U.S.

2,687

380

429

303

290

228

185

872

International

3,139

372

444

84

496

364

66

1,313

Total reported

5,826

752

873

387

786

592

251

2,185

% Change vs. 3Q25

U.S.

6.6

9.0

18.1

8.4

3.4

(11.1)

(5.6)

9.4

International

7.2

10.4

12.2

(2.7)

6.7

12.2

13.6

4.2

Total reported

6.9

9.7

15.0

5.8

5.4

1.9

(1.2)

6.2

Total reported excl. foreign exchange impact

7.4

10.0

15.5

6.0

5.7

2.6

(1.1)

6.7

Comparable sales growth

7.8

10.0

15.5

6.0

5.7

6.9

(1.1)

6.7

    U.S.

7.6

9.0

18.1

8.4

3.4

(2.3)

(5.6)

9.4

    International

8.0

11.0

13.1

(1.6)

7.1

13.5

13.9

4.9

Worldwide Medical Devices sales increased 6.9 percent on a reported basis and 7.8 percent on a comparable basis in the third quarter.

Sales growth in the quarter was led by double-digit growth in Electrophysiology and Rhythm Management.

In Diabetes Care, sales of continuous glucose monitors grew 7.3 percent on a reported basis and 7.7 percent on a comparable basis.

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total

Rhythm
Management

Electro-
physiology*

Heart
Failure

Vascular

Structural
Heart*

Neuro-
modulation

Diabetes
Care

U.S.

7,890

1,096

1,227

908

875

677

551

2,556

International

9,328

1,083

1,295

269

1,491

1,090

203

3,897

Total reported

17,218

2,179

2,522

1,177

2,366

1,767

754

6,453

% Change vs. 9M25

U.S.

7.1

10.4

16.0

10.2

5.2

(10.2)

(2.4)

9.3

International

11.7

13.9

14.5

7.9

8.0

16.1

18.1

10.5

Total reported

9.6

12.1

15.2

9.7

7.0

4.4

2.4

10.0

Total reported excl. foreign exchange impact

7.8

10.6

13.8

8.9

5.2

2.6

1.3

7.7

Comparable sales growth

8.2

10.6

13.8

8.9

5.2

6.5

1.3

7.7

    U.S.

8.1

10.4

16.0

10.2

5.2

(2.3)

(2.4)

9.3

    International

8.3

10.8

11.9

4.6

5.2

12.8

13.5

6.6

*Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the third quarter of 2025 and $156 million of sales in the first nine months of 2025 were moved from Structural Heart to Electrophysiology.

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Abbott's Financial Guidance
Abbott projects full-year 2026 comparable sales growth to be approximately 6.0%1.

Abbott projects full-year 2026 adjusted diluted earnings per share of $5.50 to $5.55.

Abbott projects fourth-quarter 2026 adjusted diluted earnings per share of $1.62 to $1.67.

Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.

Abbott Declares 411th Consecutive Quarterly Dividend
On Sept. 17, 2026, the board of directors of Abbott declared the company's quarterly dividend of $0.63 per share. Abbott's cash dividend is payable Nov. 16, 2026, to shareholders of record at the close of business on Oct. 15, 2026.

Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

Abbott will live-webcast its third-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.

— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

In 2025, total worldwide sales were $44.328 billion, which included U.S. sales of $17.126 billion and international sales of $27.202 billion, and Abbott's Structural Heart business received $89 million of compensation payments as part of a multi-year agreement with a competitor. Also in 2025, total worldwide sales for Exact Sciences were $3.247 billion, which included U.S. sales of $3.145 billion and international sales of $102 million. Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Third Quarter Ended September 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

3Q26

3Q25

% Change

Net Sales

$13,013

$11,369

14.5

Cost of products sold, excluding amortization expense

5,628

5,075

10.9

Amortization of intangible assets

841

420

n/m

Research and development

920

766

20.1

Selling, general, and administrative

4,266

3,051

39.8

Total Operating Cost and Expenses

11,655

9,312

25.2

Operating Earnings

1,358

2,057

(34.0)

Interest expense, net

297

44

n/m

Net foreign exchange (gain) loss

(6)

(17)

n/m

Other (income) expense, net

(164)

(150)

9.4

Earnings before taxes

1,231

2,180

(43.5)

Taxes on Earnings

311

536

(42.0)

1)

Net Earnings

$920

$1,644

(44.1)

Net Earnings excluding Specified Items, as described below

$2,477

$2,278

8.7

2)

Diluted Earnings per Common Share

$0.53

$0.94

(43.6)

Diluted Earnings per Common Share, excluding Specified Items, as described below

$1.42

$1.30

9.2

2)

Average Number of Common Shares Outstanding Plus Dilutive Common Stock
Options

1,738

1,749

NOTES:

See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following section.

1)

2026 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2025 Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)

2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.557 billion, or $0.89 per share, for intangible amortization, legal settlements, acquisitions, restructuring actions, and other net expenses.

2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $634 million, or $0.36 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses.

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Nine Months Ended September 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

9M26

9M25

% Change

Net Sales

$36,770

$32,869

11.9

Cost of products sold, excluding amortization expense

15,843

14,397

10.0

Amortization of intangible assets

1,921

1,260

52.4

Research and development

2,579

2,207

16.9

Selling, general, and administrative

12,031

9,203

30.7

Total Operating Cost and Expenses

32,374

27,067

19.6

Operating Earnings

4,396

5,802

(24.2)

Interest expense, net

664

143

n/m

Net foreign exchange (gain) loss

(15)

(35)

n/m

Other (income) expense, net

(457)

(414)

10.2

Earnings before taxes

4,204

6,108

(31.2)

Taxes on earnings

1,279

1,360

(6.0)

1)

Net Earnings

$2,925

$4,748

(38.4)

Net Earnings excluding Specified Items, as described below

$6,789

$6,410

5.9

2)

Diluted Earnings per Common Share

$1.67

$2.70

(38.1)

Diluted Earnings per Common Share,

excluding Specified Items, as described below

$3.88

$3.65

6.3

2)

Average Number of Common Shares Outstanding

Plus Dilutive Common Stock Options

1,743

1,749

NOTES:

See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following section.

1)

2026 Taxes on Earnings includes the recognition of approximately $95 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 

2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 

2)

2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $3.864 billion, or $2.21 per share, for intangible amortization, legal settlements, acquisitions, restructuring actions, and other net expenses.

2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.662 billion, or $0.95 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information

Third Quarter Ended September 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

3Q26

As
Reported
(GAAP)

Specified
Items

As
Adjusted

Intangible Amortization

$      841

$      (841)

$        —

Gross Margin

6,544

904

7,448

R&D

920

(28)

892

SG&A

4,266

(761)

3,505

Other (income) expense, net

(164)

4

(160)

Earnings before taxes

1,231

1,689

2,920

Taxes on Earnings

311

132

443

Net Earnings

920

1,557

2,477

Diluted Earnings per Share

$     0.53

$     0.89

$      1.42

Specified items reflect intangible amortization expense of $841 million, legal settlements of approximately $670 million and other net expenses of $178 million associated with acquisitions, restructuring actions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

3Q25

As
Reported
(GAAP)

Specified
Items

As
Adjusted

Intangible Amortization

$      420

$     (420)

$        —

Gross Margin

5,874

470

6,344

R&D

766

(36)

730

SG&A

3,051

(47)

3,004

Other (income) expense, net

(150)

5

(145)

Earnings before taxes

2,180

548

2,728

Taxes on Earnings

536

(86)

450

Net Earnings

1,644

634

2,278

Diluted Earnings per Share

$     0.94

$      0.36

$      1.30

Specified items reflect intangible amortization expense of $420 million and other net expenses of $128 million associated with restructuring actions, costs associated with acquisitions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information

Nine Months Ended September 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

9M26

As

Reported
(GAAP)

Specified
Items

As

Adjusted

Intangible Amortization

$     1,921

$    (1,921)

$        —

Gross Margin

19,006

2,033

21,039

R&D

2,579

(77)

2,502

SG&A

12,031

(1,662)

10,369

Other (income) expense, net

(457)

(30)

(487)

Earnings before taxes

4,204

3,802

8,006

Taxes on Earnings

1,279

(62)

1,217

Net Earnings

2,925

3,864

6,789

Diluted Earnings per Share

$      1.67

$      2.21

$     3.88

Specified items reflect intangible amortization expense of $1.921 billion, legal settlements of approximately $1.070 billion and other net expenses of $811 million associated with acquisitions, restructuring actions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

9M25

As

Reported
(GAAP)

Specified
Items

As

Adjusted

Intangible Amortization

$    1,260

$   (1,260)

$        —

Gross Margin

17,212

1,396

18,608

R&D

2,207

(83)

2,124

SG&A

9,203

(58)

9,145

Other (income) expense, net

(414)

(31)

(445)

Earnings before taxes

6,108

1,568

7,676

Taxes on Earnings

1,360

(94)

1,266

Net Earnings

4,748

1,662

6,410

Diluted Earnings per Share

$     2.70

$      0.95

$     3.65

Specified items reflect intangible amortization expense of $1.260 billion and other net expenses of $308 million associated with restructuring actions, acquisitions, investment impairment charges, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

A reconciliation of the third-quarter tax rates for 2026 and 2025 is shown below: 

3Q26

($ in millions)

Pre-Tax

Income

Taxes on

Earnings

Tax

Rate

As reported (GAAP)

$     1,231

$       311

25.3 %

1)

Specified items

1,689

132

Excluding specified items

$    2,920

$      443

15.2 %

3Q25

($ in millions)

Pre-Tax

Income

Taxes on

Earnings

Tax

Rate

As reported (GAAP)

$    2,180

$      536

24.6 %

2)

Specified items

548

(86)

Excluding specified items

$    2,728

$      450

16.5 %

1)

2026 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)

2025 Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

A reconciliation of the year-to-date tax rates for 2026 and 2025 is shown below: 

9M26

($ in millions)

Pre-Tax

Income

Taxes on

Earnings

Tax

Rate

As reported (GAAP)

$   4,204

$    1,279

30.4 %

3)

Specified items

3,802

(62)

Excluding specified items

$   8,006

$     1,217

15.2 %

9M25

($ in millions)

Pre-Tax

Income

Taxes on

Earnings

Tax

Rate

As reported (GAAP)

$    6,108

$    1,360

22.3 %

4)

Specified items

1,568

(94)

Excluding specified items

$    7,676

$    1,266

16.5 %

3)

2026 Taxes on Earnings includes the recognition of approximately $95 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

4)

2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Abbott Laboratories and Subsidiaries

Non-GAAP Revenue Reconciliation

Third Quarter Ended September 30, 2026 and 2025

($ in millions)

(unaudited)

3Q26

3Q25

% Change vs. 3Q25

Non-GAAP

Abbott
Reported

Foreign
exchange

Comparable
Revenue

Abbott
Reported

Impact of
acquisition (a)

Impact

of multi-year
agreement (b)

Comparable
Revenue

Reported

Comparable

Total Company

13,013

40

13,053

11,369

851

(23)

12,197

14.5

7.0

U.S.

5,504

—

5,504

4,299

824

(23)

5,100

28.0

7.9

Intl

7,509

40

7,549

7,070

27

—

7,097

6.2

6.4

Total Diagnostics

3,305

(2)

3,303

2,253

851

—

3,104

46.7

6.4

U.S.

1,853

—

1,853

886

824

—

1,710

109.2

8.4

Intl

1,452

(2)

1,450

1,367

27

—

1,394

6.2

4.0

Total Cancer Diagnostics

968

—

968

—

851

—

851

n/a

13.8

U.S.

938

—

938

—

824

—

824

n/a

13.9

Intl

30

—

30

—

27

—

27

n/a

12.1

Total Medical Devices

5,826

22

5,848

5,448

—

(23)

5,425

6.9

7.8

U.S.

2,687

—

2,687

2,521

—

(23)

2,498

6.6

7.6

Intl

3,139

22

3,161

2,927

—

—

2,927

7.2

8.0

Total Structural Heart*

592

4

596

580

—

(23)

557

1.9

6.9

U.S.

228

—

228

256

—

(23)

233

(11.1)

(2.3)

Intl

364

4

368

324

—

—

324

12.2

13.5

*

Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the third quarter of 2025 were moved from Structural Heart to Electrophysiology.

a)

The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.

b)

Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Abbott Laboratories and Subsidiaries

Non-GAAP Revenue Reconciliation

Nine Months Ended September 30, 2026 and 2025

($ in millions)

(unaudited)

9M26

9M25

% Change vs. 9M25

Non-GAAP

Abbott
Reported

Impact of
acquisition (a)

Impact

of multi-year
agreement (b)

Foreign
exchange

Comparable
Revenue

Abbott
Reported

Impact of
acquisition (a)

Impact

of multi-year
agreement (b)

Comparable
Revenue

Reported

Comparable

Total Company

36,770

706

(8)

(460)

37,008

32,869

2,369

(69)

35,169

11.9

5.2

U.S.

14,994

681

(8)

—

15,667

12,743

2,294

(69)

14,968

17.7

4.7

Intl

21,776

25

—

(460)

21,341

20,126

75

—

20,201

8.2

5.7

Total Diagnostics

8,577

706

—

(100)

9,183

6,480

2,369

—

8,849

32.4

3.8

U.S.

4,418

681

—

—

5,099

2,568

2,294

—

4,862

72.0

4.9

Intl

4,159

25

—

(100)

4,084

3,912

75

—

3,987

6.3

2.4

Total Cancer Diagnostics

1,983

706

—

(1)

2,688

—

2,369

—

2,369

n/a

13.5

U.S.

1,921

681

—

—

2,602

—

2,294

—

2,294

n/a

13.5

Intl

62

25

—

(1)

86

—

75

—

75

n/a

15.0

Total Medical Devices

17,218

—

(8)

(284)

16,926

15,712

—

(69)

15,643

9.6

8.2

U.S.

7,890

—

(8)

—

7,882

7,363

—

(69)

7,294

7.1

8.1

Intl

9,328

—

—

(284)

9,044

8,349

—

—

8,349

11.7

8.3

Total Structural Heart*

1,767

—

(8)

(31)

1,728

1,692

—

(69)

1,623

4.4

6.5

U.S.

677

—

(8)

—

669

753

—

(69)

684

(10.2)

(2.3)

Intl

1,090

—

—

(31)

1,059

939

—

—

939

16.1

12.8

*

Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $156 million of sales in the first nine months of 2025 were moved from Structural Heart to Electrophysiology.

a)

The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.

b)

Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Abbott Laboratories and Subsidiaries

Details of Specified Items

Third Quarter Ended September 30, 2026

(in millions, except per share data)

(unaudited)

Acquisition or
Divestiture-
related (a)

Restructuring
and Cost
Reduction
Initiatives (b)

Intangible
Amortization

Other (c)

Total
Specifieds

Gross Margin

$          10

$             29

$         841

$           24

$        904

R&D

(7)

(5)

—

(16)

(28)

SG&A

(47)

(20)

—

(694)

(761)

Other (income) expense, net

(8)

(1)

—

13

4

Earnings before taxes

$           72

$             55

$         841

$          721

1,689

Taxes on Earnings (d)

132

Net Earnings

$      1,557

Diluted Earnings per Share

$        0.89

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans.

c)

Other primarily includes approximately $670 million related to agreements entered into to resolve the Gill case and the necrotizing enterocolitis (NEC) claims asserted on behalf of approximately 2,000 additional infants, as well as incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)

Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Abbott Laboratories and Subsidiaries

Details of Specified Items

Third Quarter Ended September 30, 2025

(in millions, except per share data)

(unaudited)

Acquisition or
Divestiture-
related (a)

Restructuring
and Cost
Reduction
Initiatives (b)

Intangible
Amortization

Other (c)

Total
Specifieds

Gross Margin

$           —

$             44

$         420

$            6

$         470

R&D

—

(19)

—

(17)

(36)

SG&A

(9)

(43)

—

5

(47)

Other (income) expense, net

7

—

—

(2)

5

Earnings before taxes

$            2

$            106

$         420

$           20

548

Taxes on Earnings (d)

(86)

Net Earnings

$         634

Diluted Earnings per Share

$        0.36

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.

c)

Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)

Reflects the net tax benefit associated with the specified items. Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Abbott Laboratories and Subsidiaries

Details of Specified Items

Nine Months Ended September 30, 2026

(in millions, except per share data)

(unaudited)

Acquisition or
Divestiture-
related (a)

Restructuring
and Cost
Reduction
Initiatives (b)

Intangible
Amortization

Other (c)

Total
Specifieds

Gross Margin

$          44

$             40

$        1,921

$           28

$       2,033

R&D

(18)

(15)

—

(44)

(77)

SG&A

(533)

(54)

—

(1,075)

(1,662)

Other (income) expense, net

(9)

(4)

—

(17)

(30)

Earnings before taxes

$         604

$             113

$        1,921

$        1,164

3,802

Taxes on Earnings (d)

(62)

Net Earnings

$       3,864

Diluted Earnings per Share

$         2.21

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include stock-based compensation recognized as expense from equity awards accelerated in connection with the Exact Sciences acquisition, integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions, including inventory step-up amortization.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans.

c)

Other primarily includes approximately $670 million related to agreements entered into to resolve the Gill case and the NEC claims asserted on behalf of approximately 2,000 additional infants; approximately $400 million, including attorneys' fees and accrued interest, related to an agreement to resolve the United States Department of Justice (DOJ) investigations and the civil qui tam lawsuit brought by certain relators and joined by the DOJ and Attorneys General of several states; as well as incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)

Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Abbott Laboratories and Subsidiaries

Details of Specified Items

Nine Months Ended September 30, 2025

(in millions, except per share data)

(unaudited)

Acquisition or
Divestiture-
related (a)

Restructuring
and Cost
Reduction
Initiatives (b)

Intangible
Amortization

Other (c)

Total
Specifieds

Gross Margin

$            1

$            125

$       1,260

$           10

$       1,396

R&D

(1)

(42)

—

(40)

(83)

SG&A

(15)

(49)

—

6

(58)

Other (income) expense, net

(18)

—

—

(13)

(31)

Earnings before taxes

$           35

$            216

$       1,260

$           57

1,568

Taxes on Earnings (d)

(94)

Net Earnings

$       1,662

Diluted Earnings per Share

$        0.95

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.

c)

Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments.

d)

Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

SOURCE Abbott

Perpetual Ltd trimmed its position in Abbott Laboratories (NYSE:ABT – Free Report) by 5.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 444,048 shares of the healthcare product maker’s stock after selling 26,238 shares during the quarter. Perpetual Ltd’s holdings in Abbott Laboratories were worth $43,885,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Cornerstone Financial Management LLC bought a new stake in shares of Abbott Laboratories in the fourth quarter valued at about $25,000. Purpose Unlimited Inc. bought a new position in Abbott Laboratories during the fourth quarter worth about $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in Abbott Laboratories in the 4th quarter worth about $26,000. Abound Financial LLC acquired a new stake in Abbott Laboratories in the 4th quarter worth about $26,000. Finally, Manning & Napier Advisors LLC acquired a new stake in Abbott Laboratories in the 2nd quarter worth about $31,000. Institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth A number of research analysts have issued reports on the stock. Wells Fargo & Company increased their target price on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Rothschild & Co Redburn raised shares of Abbott Laboratories from a “neutral” rating to a “buy” rating and raised their target price for the stock from $119.00 to $127.00 in a report on Friday, October 2nd. Citigroup lifted their price target on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, July 17th. TD Cowen reiterated a “buy” rating and issued a $135.00 price target on shares of Abbott Laboratories in a research note on Tuesday, September 8th. Finally, Barclays initiated coverage on Abbott Laboratories in a research note on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 price target for the company. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $118.88.

Read Our Latest Analysis on ABT Abbott Laboratories Stock Performance ABT opened at $101.79 on Tuesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $133.34. The firm has a market cap of $176.13 billion, a P/E ratio of 32.94, a price-to-earnings-growth ratio of 1.85 and a beta of 0.59. The business’s fifty day moving average is $106.14 and its 200-day moving average is $98.29.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%. Abbott Laboratories’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

(Free Report)

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.

Featured Articles Five stocks we like better than Abbott Laboratories Salesforce Just Got a Rare Double Upgrade—What Changed? OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit 3 REITs That May Win in a Higher Interest Rate Environment Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Abbott (ABT +1.13%) currently trades for less than $100 a share. A conservative base-case model suggests the healthcare stock could be worth around $210 per share a decade from now. The best part is that doubling doesn't require anything close to optimistic assumptions; it's grounded in Abbott's recent history.

This high upside potential from a low-risk, high-quality dividend stock is why I just added Abbott to my portfolio this week.

Image source: The Motley Fool.

A history lessonIn 2016, Abbott generated nearly $21 billion in sales and $2.20 per share of adjusted earnings. This year, the healthcare company expects to report about $47 billion in sales and $5.53 of earnings at the mid-point of its current guidance range. That's a 9.7% compound annual earnings-per-share growth rate over the past decade.

Acquisitions helped Abbott deliver a nearly double-digit compound annual earnings growth rate over the past decade. In 2017, it bought both St. Jude Medical and Alere for $25 billion and $5.8 billion, respectively. These deals enhanced its operations and earnings (both were accretive in the first full year). The company also bought Exact Sciences earlier this year for $21 billion, a move that is boosting its 2026 results.

Premium Feature

Moneyball Superscore

74/100

Today's Change

(

1.13

%) $

1.11

Current Price

$

99.60

Abbot's share price has followed its revenue and earnings higher. It's up 130% over the last 10 years (8.7% annualized total return). That doesn't include dividends. Add in Abbott's steadily rising dividend, and the total return with dividends reinvested is more than 175% (10.7% annualized). Abbott has increased its dividend for 54 consecutive years, qualifying it as a Dividend King (a company with 50 or more years of annual dividend increase).

The math to $210 (or more) by 2036I considered several scenarios when evaluating Abbott for my portfolio. I settled on a base case in which Abbott Labs grows its earnings at a 8% compound annual rate over the next decade. I chose that more conservative rate because acquisitions played a meaningful role in driving growth over the past 10 years. Under this conservative scenario, Abbott's earnings would grow to about $11.93 per share by 2036. Assuming a 17.5x valuation multiple (Abbott currently trades at about 18x forward earnings), that would put its share price at around $210.

That doesn't include Abbott's dividend, which currently yields 2.5%, more than double the S&P 500's level of around 1%. The company would likely continue to grow that payout at a mid-to-high single-digit annual rate (it hiked its dividend by 6.8% this year and has grown it by 70% since 2020).

Abbott fits perfectly with my current financial plan. I'm seeking more resilient, income-focused holdings to set me up for an early retirement if AI ever disrupts my job. Abbott checks every box. It provides durable, steadily rising dividend income backed by a diversified portfolio of healthcare technologies, including diagnostics, medical devices, nutritionals, and branded generic medicines. It's the exact type of defensive holding I'm seeking to provide more ballast.

Further, Abbott provides a strong defense without giving up any offensive upside. With a 2.5% dividend yield and earnings growing conservatively at 8% annually, Abbott could generate double-digit annual returns over the next 10 years. That strong return doesn't require any large acquisitions to boost its results. Meanwhile, faster acquisition-driven growth would position Abbott to generate even higher returns. For example, a 9%+ earnings growth rate with a slightly higher valuation multiple would push the stock price toward $250 by 2036.

I also like that the downside risk is low. The company does have risks, including integrating Exact Sciences and managing the heavier debt load from that all-cash deal. However, even if growth slowed and its valuation multiple continued to fall, Abbott should still be worth more in a decade than it is today while also providing a steadily rising income stream.

Abbott's history says it has a bright futureAbbott has historically grown its earnings at a nearly 10% compound annual rate over the last decade. It doesn't need to grow that fast in the future to deliver a very favorable outcome for shareholders, as 8% annual earnings-per-share growth could double its share price by 2036, with its steadily rising, high-yielding dividend adding to the total return. That's exactly the lower-risk, higher-upside investment I'm seeking to make these days, which is why I just added Abbott to my portfolio. I expect to build this position into a meaningful part of my financial independence plan.

For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App Rising PAP can signal worsening heart failure weeks before patients experience symptoms New capabilities help patients take a more active role in their care and stay connected to their care teams between doctor visits , /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) approval for updates to the CardioMEMS HF System that enable new patient-facing capabilities through the CardioGuide HF App. For the first time, care teams can allow U.S. CardioMEMS patients to view their pulmonary artery pressure (PAP) readings directly on their smartphones, giving them greater insight into their condition and helping them take a more active role in their care.

Heart failure can worsen long before symptoms become noticeable. Pulmonary artery pressure — the pressure of blood flowing from the heart to the lungs — can rise as heart failure worsens, often weeks before patients experience any symptoms. The CardioMEMS HF System, which has been shown to reduce heart failure hospitalizations2,3 and mortality risk4,5, measures pulmonary artery pressure through an implanted sensor in the pulmonary artery. For more than a decade, clinicians have used pulmonary artery pressure readings from the CardioMEMS HF System to help identify signs of worsening heart failure and guide treatment.

Building on that clinical experience with CardioMEMS, Abbott is continuing to evolve heart failure management with digital tools that help keep clinicians and patients connected between office visits. The CardioMEMS HF System with the CardioGuide HF App represents an important step toward helping patients take an earlier, more active role in understanding and managing their heart failure.

"Heart failure can worsen before patients notice shortness of breath, swelling or weight gain. Pulmonary artery pressure readings can help identify changes earlier, giving care teams an opportunity to adjust treatment before symptoms develop," said Andrew J. Sauer, M.D., cardiologist and vice president for research at Saint Luke's Mid America Heart Institute and professor of medicine at the University of Missouri-Kansas City. "By giving patients access to their pressure trends and personalized guidance from their care team, the CardioGuide HF App can help patients better understand their condition, understand why treatment adjustments are recommended, and take a more active role in managing their heart failure."

The new CardioMEMS HF System capabilities also include Dynamic Treatment Plan (DTP), a software feature that allows clinicians to set up personalized medication adjustment plans based on changes in a patient's pulmonary artery pressure. Once in place, DTP can send medication adjustment instructions directly to CardioMEMS patients through the CardioGuide HF App, ensuring patients receive timely feedback and guidance from their care team.

"Abbott is reshaping heart failure care by bringing meaningful, actionable information directly to patients," said Katie Spayde, vice president of Abbott's heart failure division. "For many people living with heart failure, managing their condition is part of everyday life. By giving patients greater visibility into their condition, these new capabilities help them stay informed, engaged and connected to their care between doctor visits."

Abbott plans to make CardioGuide HF App and Dynamic Treatment Plan available later this year.

Frequently Asked Questions

What is heart failure?
Heart failure is a chronic, progressive condition in which the heart is unable to pump enough blood to meet the body's needs. It can cause shortness of breath, fatigue and swelling, and tends to worsen over time. Heart failure affects millions of people worldwide and is a leading cause of hospitalization.

What is pulmonary artery pressure, and why does it matter in heart failure?
Pulmonary artery pressure is the pressure of blood flowing from the right side of the heart into the lungs. Rising pulmonary artery pressure is one of the earliest signs of worsening heart failure, often before a patient feels any symptoms. Monitoring pulmonary artery pressure remotely helps clinicians detect these changes early and adjust treatment before hospitalization is needed.

What is the CardioGuide HF App?
The CardioGuide HF App is a mobile app for people living with heart failure who have a CardioMEMS pulmonary artery pressure sensor. The app displays a patient's own pulmonary artery pressure readings and trends on their iOS or Android smartphone.

How does the CardioGuide HF App work with the CardioMEMS HF System?
The CardioMEMS HF System includes an implanted pulmonary artery pressure sensor, the CardioMEMS HERO device and the Merlin.net Patient Care Network Portal.

Individuals implanted with a CardioMEMS sensor can use the CardioMEMS HERO device to take pressure readings, which are transmitted to their care team through the Merlin.net Patient Care Network Portal. The CardioGuide HF App complements the system by giving patients direct visibility into their pulmonary artery pressure readings and trends on their smartphones.

Together, the CardioMEMS HF System and CardioGuide HF App help keep both clinicians and patients informed and engaged in heart failure management.

What is the Dynamic Treatment Plan?
Dynamic Treatment Plan (DTP) is a feature available through Abbott's Merlin.net Patient Care Network Portal that enables care teams to communicate treatment plan updates directly to CardioMEMS patients through the CardioGuide HF App. When enabled by a clinician, patients can receive updates related to their individual heart failure management plan through the CardioGuide HF App.

About the CardioMEMS HF System
Abbott's CardioMEMS HF System is the leading remote hemodynamic monitoring platform for heart failure patients. The system features a small pressure-sensing device implanted permanently in the pulmonary artery. The device allows clinicians to remotely monitor pulmonary artery pressure through the Merlin.net Patient Care Network Portal and proactively adjust treatment before hospitalization is needed. Supported by more than a decade of clinical evidence, CardioMEMS is the most-studied1 and only FDA-approved wireless heart failure monitoring system proven to reduce heart failure hospitalizations2,3 and mortality risk4,5. Additional information about the CardioMEMS HF System is available here.

Indications and Important Safety Information
For U.S. important safety information on the CardioMEMS HF System, visit: Indications, Safety and Warnings for the CardioMEMS HF System.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X, and YouTube. 

1Abbott. Data on file.
2Heywood JT, Zalawadiya S, Bourge RC, et al. Sustained reduction in pulmonary artery pressures and hospitalizations during 2 years of ambulatory monitoring. J Card Fail. 2023;29(1):56–66. doi: 10.1016/j.cardfail.2022.10.422.
3Adamson PB, Abraham WT, Stevenson LW, et al. Pulmonary artery pressure-guided heart failure management reduces 30-day readmissions. Circ Heart Fail. 2016;9(6):e002600. doi:10.1161/CIRCHEARTFAILURE.115.002600.
4Lindenfeld J, Costanzo MR, Zile MR, et al., on behalf of the GUIDE-HF, CHAMPION, and LAPTOP-HF Investigators. Meta-Analysis of Implantable Hemodynamic Monitors for HFrEF. Implantable hemodynamic monitors improve survival in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2024;83:682-694. doi:10.1016/j.jacc.2023.11.030.
5Zalawadiya S, Abraham J, Rathman L, et al. Early reduction of pulmonary artery pressures is associated with improved mortality among Medicare beneficiaries with heart failure. JACC Heart Fail. 2025;13(10):102589. doi:10.1016/j.jchf.2025.102589.

SOURCE Abbott

Engineers Gate Manager LP reduced its position in Abbott Laboratories (NYSE:ABT – Free Report) by 97.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,990 shares of the healthcare product maker’s stock after selling 165,381 shares during the period. Engineers Gate Manager LP’s holdings in Abbott Laboratories were worth $453,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Aureus Asset Management LLC boosted its holdings in shares of Abbott Laboratories by 25.0% during the first quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock worth $34,078,000 after purchasing an additional 66,422 shares during the last quarter. Thompson Investment Management Inc. lifted its position in Abbott Laboratories by 786.0% during the second quarter. Thompson Investment Management Inc. now owns 14,061 shares of the healthcare product maker’s stock worth $1,276,000 after buying an additional 12,474 shares during the period. Parnassus Investments LLC boosted its stake in Abbott Laboratories by 17.5% in the 4th quarter. Parnassus Investments LLC now owns 616,351 shares of the healthcare product maker’s stock worth $77,223,000 after buying an additional 91,897 shares during the last quarter. Clear Harbor Asset Management LLC acquired a new stake in Abbott Laboratories in the 2nd quarter worth about $4,889,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Abbott Laboratories by 38.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,895,185 shares of the healthcare product maker’s stock valued at $171,969,000 after buying an additional 522,279 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Performance Shares of ABT stock opened at $103.62 on Thursday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The company’s fifty day moving average price is $107.15 and its two-hundred day moving average price is $99.10. The firm has a market capitalization of $179.31 billion, a P/E ratio of 33.53, a P/E/G ratio of 1.92 and a beta of 0.59. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $136.83.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same period in the previous year, the company earned $1.26 earnings per share. The company’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year. Abbott Laboratories Dividend Announcement The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Wall Street Analyst Weigh In Several research analysts have recently weighed in on ABT shares. TD Cowen reiterated a “buy” rating and set a $135.00 price objective on shares of Abbott Laboratories in a report on Tuesday, September 8th. Piper Sandler reaffirmed an “overweight” rating and set a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Bank of America cut their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. The Goldman Sachs Group lowered their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Finally, Weiss Ratings upgraded Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, September 18th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $119.50.

Check Out Our Latest Stock Report on Abbott Laboratories

Trending Headlines about Abbott Laboratories Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Abbott and Berry Street announced an exclusive partnership combining Abbott’s Lingo over-the-counter continuous glucose monitor with Berry Street’s insurance-covered registered-dietitian and nutrition-coaching platform. The initiative could improve Lingo adoption, expand Abbott’s consumer health ecosystem and strengthen its position in metabolic-health services. Abbott and Berry Street partnership article Positive Sentiment: Abbott’s Volt Pulsed Field Ablation System reportedly saw its first clinical use in Canada and at an Illinois heart center for treating atrial fibrillation. Additional real-world use could support the medical-device pipeline and future cardiovascular revenue growth. Abbott digital health and formula settlement article Positive Sentiment: Investor commentary continues to describe Abbott as a high-quality, diversified healthcare business with attractive long-term prospects. Its exposure to diagnostics, medical devices, nutrition and digital health provides multiple growth avenues, and the therapeutic drug-monitoring market is projected to expand substantially through 2032. What makes Abbott attractive article Neutral Sentiment: ABT is drawing increased attention from investors and analysts. Recent results exceeded consensus estimates, with revenue growth supported by the company’s diversified portfolio, but commentary generally characterizes the shares as a strong business available at a fair—not deeply discounted—price. Abbott trending stock article Negative Sentiment: Abbott agreed to pay approximately $385 million to settle infant-formula litigation. Although the settlement removes some legal uncertainty, the cash cost and reputational overhang are negative for near-term sentiment. Valuation comparisons with faster-growing healthcare companies, including Exact Sciences, may also reduce enthusiasm among growth-oriented investors. Abbott and Exact Sciences comparison article (Free Report)

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.

Featured Stories Five stocks we like better than Abbott Laboratories Chips to Bots: Qualcomm’s Agentic AI Breakout Ciena Fell 40%—Now One Analyst Sees 50% Upside Energy Transfer Taps the AI Power Boom Viking’s Obesity Edge May Be Staying Power, Not Weight Loss Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

A Dividend King is a company that's raised its dividend for at least 50 years consecutively. Abbott Laboratories (ABT -0.13%), for example, is one such company, having raised its dividend for 54 straight years. But that's not really why Wall Street is bullish on the stock. It's that Abbott is proving it can increases earnings faster than expected, thanks to its Medical Devices segment picking up steam. That's great news for income investors.

Image source: Getty Images.

Why all the excitement around Abbott Laboratories Abbott's second-quarter 2026 earnings gave investors a good reason to be bullish. Sales rose 13% to about $12.6 billion, while adjusted earnings per share (EPS) rose to $1.31. The healthcare company also raised full-year adjusted EPS forecast to $5.45 to $5.60, while keeping comparable sales growth projections at 6.5% to 7.5%.

You can see the result in recent analyst ratings and targets. Based on the latest analyst data, Abbott has 21 "buy" ratings and one "hold" among 29 analysts, with mean-to-high target prices of $121.33 to $143. TD Cowen lifted its target to $135 from $115, Citi raised its target to $125 from $112, and Wolfe Research upgraded Abbott to "outperform" with a $130 target.

The real question is whether its businesses can sustain earnings growth for years to come.

Premium Feature

Moneyball Superscore

74/100

Today's Change

(

-0.13

%) $

-0.13

Current Price

$

102.23

The Medical Devices segment is reshaping Abbott's growth story Abbott's Medical Devices segment is becoming its main growth story. The segment grew 8.4% on a comparable basis and generated almost $6 billion of second-quarter sales, led by electrophysiology.

The diabetes business is another bright spot, with continuous glucose monitor sales rising during the quarter. The rollout of Libre Duo, which adds ketone monitoring, gives Abbott another product that could help extend the Libre franchise.

Then there's cancer diagnostics. Abbott closed its $21 billion acquisition of Exact Sciences in March, adding Cologuard and expanding its presence in cancer screening. The deal should pay off over time, though it will weigh on near-term earnings before expected cost savings kick in.

So the next logical question would be: Can all this growth translate into stronger earnings and cash flow to support its dividends?

Why the dividend still hinges on earnings growth Abbott's record of paying dividends should give income investors a reason to smile. The company has raised its dividend for 54 consecutive years, while its operating cash flow of $3.8 billion in the first half of 2026 continues to support its payouts.

But here's the challenge: Not every part of Abbott is growing at the same pace. Its Nutrition and Rapid and Molecular Diagnostics segments declined in the second quarter, leaving faster-growing areas such as Medical Devices to carry more of the burden of driving the company's overall earnings.

This matters because Abbott's stock isn't cheap. It's trading at about 33 times earnings, which already prices in stronger future gains. In other words, there's less room for error if growth or its execution falls short.

What this growth outlook means for income investors So, why is Wall Street bullish on Abbott? Put simply, it's because of the growth outlook. Medical Devices is gaining momentum, Libre keeps expanding its reach, and Exact Sciences opens up a new source of growth through cancer screening. All together, these segments offer Abbott more opportunities to increase its earnings and, by extension, its dividend.

For anyone seeking a mix of income and growth, Abbott has become a more compelling income option. Yes, the stock trades at a valuation that already reflects some optimism. However, if Abbott's strongest businesses continue to deliver, Wall Street's bullish call could prove correct.

Settlement does not represent any finding of fault or liability As the government has previously indicated, it has closed its criminal investigation on this matter Tests by government regulators of unopened product from the homes of the infants under investigation at the time of the 2022 recall were negative for Cronobacter sakazakii No unopened, distributed Abbott infant formulas have ever tested positive for Cronobacter sakazakii , /PRNewswire/ -- Abbott (NYSE: ABT) has reached an agreement to resolve the previously disclosed investigation and lawsuit brought by the United States Department of Justice, as well as lawsuits filed by certain relators and the Attorneys General of several states, relating to Abbott's manufacturing and 2022 recall of powdered infant formula at its facility in Sturgis, Mich.

Abbott will pay a total of $385 million to resolve the claims. The settlement does not represent any finding of fault or liability.

Additionally, as the government has previously indicated, it has closed its criminal investigation regarding this matter.

Importantly, no unopened, distributed Abbott infant formulas have ever tested positive for Cronobacter sakazakii. Consistent with this, the FDA confirmed in early March 2022 that the unopened product from the homes of the infants under investigation at the time of the 2022 recall tested negative for Cronobacter sakazakii. The CDC later concluded there was no definitive link between the Sturgis facility and the clinical cases under investigation at that time. Read more details below in Frequently Asked Questions.

Nothing matters more than the safety and quality of Abbott's products. We make infant formula with the same care we would for our own families and are deeply committed to earning and maintaining caregivers' trust. As we move forward, Abbott remains focused on serving the families who depend on us every day.

Frequently Asked Questions:

What is Cronobacter, and where is it commonly found?

Cronobacter is a ubiquitous bacterium that is known to harbor in homes (especially kitchens), bottled water and unsanitized feeding equipment (like breast pumps), as well as all infant formula manufacturing facilities. A study published in July 2024 in the American Society for Microbiology's Applied and Environmental Microbiology journal showed that out of 263 households in the U.S., 36% had at least one environmental positive swab for Cronobacter spp. and 25% had Cronobacter sakazakii, confirming its ubiquity. And those findings were based on an average of just 10 swabs per house. Were the lots of the products consumed by these infants tested for Cronobacter sakazakii? 
Yes, they were tested. No unopened, distributed Abbott infant formulas have ever tested positive for Cronobacter sakazakii or Salmonella Newport.

Additionally:

Abbott retains samples from all lots of all products distributed. Samples from the lots that corresponded to those that were consumed by the infants were tested. All tested negative. Genetic sequencing on the available samples from two of the ill infants did not match the strains of Cronobacter found in the plant. Nor did the available samples from the infants match one another, indicating that the two cases did not have a common source. That's important because microbiologists tell us that the DNA sequence is a critical element for determining origin. Institutions performing the testing of the other three infants did not retain or provide the clinical sample for Whole Genome Sequencing (WGS). The lack of this data is not a miss from Abbott Nutrition. What did government regulators' testing of the formula linked to the reported infant illnesses reveal?
In all five cases, the state, FDA, and/or CDC tested samples of the Abbott formula that was used by the child.

In all five cases, all unopened containers tested negative. Open containers from the homes of the infants were also tested in four of the five cases; three of the four tested negative. The one positive was from an open container from the home of the infant, and it tested positive for two different strains of Cronobacter sakazakii, neither of which were found in the Sturgis plant. In fact, one matched the strain that caused the infant's infection, and the other matched a strain found on a bottle of distilled water in the home used to mix the formula. Notably, these findings are significant because it was these five complaints that ultimately were the reason for the recall. Further, FDA testing of product batches and retained product samples collected from the Sturgis facility during the inspection were all negative for Cronobacter sakazakii and Salmonella. We later learned in March 2023 through a CDC report that Cronobacter sakazakii was recovered from breast pump parts used in the home of one of the four infants the FDA was investigating in 2022. Has the CDC commented on Abbott's recall in Sturgis?
In a video posted by the National Academies, CDC scientists look back on the Sturgis recall; in particular, Dr. Julia Haston explains (presentation beginning at approximately 1:03), among other things:

The cases did not meet the definition of an "outbreak." There was "no definitive link" between the Sturgis facility and the cases investigated. One of the four cases was "linked to PIF [powdered infant formula] that was likely contaminated in the home after the formula was opened." CDC's investigation found five invasive Cronobacter infections unrelated to the Sturgis facility. Powdered infant formula investigations "most often suggest that contamination [with Cronobacter] occurs in the home." "For Cronobacter, most cases linked to infant formula are not associated with an outbreak." Have other infant formula manufacturers experienced similar issues? 
Yes. Following Abbott's 2022 recall, multiple infant formula manufacturers have reported Cronobacter-related findings in manufacturing facilities, and in one instance, in finished, distributed product.

What should parents and caregivers take away? 
The CDC states:

Cronobacter bacteria are found naturally in the environment. Cronobacter bacteria can contaminate dry foods, including powdered infant formula, and feeding items like breast pump equipment. To prevent babies from getting Cronobacter infection: Breastfeed if you can. Clean, sanitize and store infant feeding items safely. Keep hands and surfaces clean. Prepare and store formula safely. About Abbott: 
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, and on LinkedIn, Facebook, Instagram, X and YouTube. 

SOURCE Abbott

With doubts around geopolitical issues combined with the stock market trading near record highs, it's natural to wonder whether a painful sell-off is overdue. If it is, Abbott Laboratories (ABT -0.42%) could be one of the best dividend stocks to own through the storm. Abbott is a Dividend King, a company that has increased its dividend for at least 50 consecutive years. In Abbott's case, it has raised its dividend for the past 54 consecutive years.

If the market crashes, Abbott could provide investors with a stable income stream, helping to soften the blow as they wait for a recovery.

The bigger question now is whether Abbott can keep it going.

Image source: Getty Images.

Abbott's dividend looks sustainable, even in a slowdown In the second quarter, the company reported sales of $12.6 billion, up 13% year over year, while adjusted diluted earnings per share (EPS) came in at $1.31, beating Wall Street expectations. Management is confident that momentum can continue, as the company raised its full-year adjusted EPS forecast to between $5.45 and $5.60 per share.

Meanwhile, Abbott's dividend payout ratio is about 46%, meaning the company pays out less than half of its earnings as dividends. For dividend investors, that means Abbott earns more than enough to keep paying shareholders while still leaving room to reinvest in the business. And the more the business grows, the more it can support future dividend increases.

In fact, Abbott returned $2.1 billion to shareholders in the second quarter alone through a combination of share repurchases and dividends. Today, the stock's forward dividend yield is roughly 2.3%.

So, can Abbott keep increasing its dividends?

Premium Feature

Moneyball Superscore

74/100

Today's Change

(

-0.42

%) $

-0.46

Current Price

$

108.33

New products and a major deal could lift growth in 2026 Management believes sales and earnings will accelerate in the second half of 2026, creating a favorable setup for continued dividend increases. Abbott's medical devices business has been one of its bright spots.

The segment is seeing solid growth thanks to the U.S. launch of the Volt PFA system and the international rollout of Volt and TactiFlex Duo, devices used to treat certain heart conditions.

But perhaps the biggest catalyst this year was Abbott's $21 billion acquisition of Exact Sciences. With the deal, Abbott is expanding into the fast-growing cancer diagnostics market. Granted, the acquisition closed only in March, so there is still plenty of runway ahead, especially as the new business contributes more to earnings.

Investors are already seeing promising signs that this investment is paying off. Revenue in Abbott's cancer diagnostics segment grew 13.3% in the second quarter, driven by precision oncology, international growth, and Cologuard, a noninvasive colorectal cancer screening test.

Looking ahead, this segment is well-positioned to deliver stronger growth in the second half of the year, especially as Abbott ramps up newly launched tests, care gap programs, and overseas expansion.

So, what do analysts think about Abbott stock?

Should dividend investors consider buying Abbott now? For dividend investors who own Abbott, the appeal is a compelling combination of income and stability. The company has raised its dividend for more than five decades, and its latest results prove that earnings and cash flow can support future payouts.

At the same time, Abbott's medical devices and cancer diagnostics businesses provide clear avenues for growth. If those segments continue to expand and generate cash, they could give Abbott an even stronger cushion to maintain and potentially raise its dividend, even if the broader market stumbles.

Wall Street appears bullish, with analyst offering "strong buy" rating on average. If a crash happens, investors will likely want holdings that can keep paying them while they wait it out, and Abbott Laboratories fits that profile.

In the latest close session, Abbott (ABT - Free Report) was up +1.41% at $110.47. This move outpaced the S&P 500's daily gain of 0.46%. Elsewhere, the Dow gained 0.56%, while the tech-heavy Nasdaq added 0.45%.

The maker of infant formula, medical devices and drugs's shares have seen an increase of 3.29% over the last month, not keeping up with the Medical sector's gain of 4.16% and outstripping the S&P 500's gain of 2%.

The upcoming earnings release of Abbott will be of great interest to investors. In that report, analysts expect Abbott to post earnings of $1.43 per share. This would mark year-over-year growth of 10%. At the same time, our most recent consensus estimate is projecting a revenue of $12.91 billion, reflecting a 13.52% rise from the equivalent quarter last year.

Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $5.52 per share and revenue of $50.32 billion. These totals would mark changes of +7.18% and +13.51%, respectively, from last year.

Investors should also pay attention to any latest changes in analyst estimates for Abbott. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.03% higher. Right now, Abbott possesses a Zacks Rank of #3 (Hold).

In the context of valuation, Abbott is at present trading with a Forward P/E ratio of 19.73. This signifies a discount in comparison to the average Forward P/E of 21.18 for its industry.

One should further note that ABT currently holds a PEG ratio of 2.02. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 1.88.

The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 97, putting it in the top 40% of all 250+ industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Aberdeen Wealth Management LLC acquired a new position in Abbott Laboratories (NYSE:ABT – Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 9,291 shares of the healthcare product maker’s stock, valued at approximately $843,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Visionary Wealth Advisors purchased a new position in shares of Abbott Laboratories during the 2nd quarter worth $348,000. Ames National Corp purchased a new stake in Abbott Laboratories in the 2nd quarter valued at about $211,000. Asset One Wealth Management LLC purchased a new stake in Abbott Laboratories in the 2nd quarter valued at about $328,000. Safeguard Investment Advisory Group LLC acquired a new position in Abbott Laboratories in the second quarter valued at about $273,000. Finally, Ally Financial Inc. purchased a new position in Abbott Laboratories during the second quarter worth about $7,350,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth ABT has been the subject of several research reports. BTIG Research lifted their target price on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a report on Friday, July 17th. Piper Sandler restated an “overweight” rating and set a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Wells Fargo & Company lifted their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective on the stock in a report on Thursday, August 13th. Finally, JPMorgan Chase & Co. raised their target price on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $119.50.

Check Out Our Latest Report on ABT Abbott Laboratories News Summary Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: New infant formula expands Abbott’s nutrition portfolio. Abbott launched Similac 360 Total Care Made With Whole Milk, described as the first commercially sterile, ready-to-feed liquid whole-milk infant formula available in the U.S. The product targets growing parental interest in whole-milk formulas while offering convenience at a price similar to Similac’s powdered formula. Wider distribution and consumer adoption could provide incremental growth for Abbott’s Nutrition segment. Abbott launches whole-milk liquid infant formula Positive Sentiment: Analysts remain optimistic despite relative underperformance. Coverage notes that ABT has lagged the broader healthcare sector over the past year, but Wall Street analysts continue to express confidence in the company’s outlook. Recent earnings also showed revenue growth, an earnings-per-share beat and reaffirmed 2026 guidance, supporting the bullish view. Abbott stock and healthcare-sector performance Neutral Sentiment: Abbott is positioning the launch around changing consumer and policy preferences. The whole-milk formula introduction aligns with interest in “Make America Healthy Again” themes, but the financial impact will depend on demand, pricing and market share gains. Abbott and the Make America Healthy Again movement Negative Sentiment: Formula-related advertising scrutiny remains a risk. In a challenge brought by Abbott, the National Advertising Division supported certain Kendamil whole-milk claims but recommended that other nutritional, ingredient and heritage claims be modified or discontinued. The decision is not a direct finding against Abbott, but it highlights competitive scrutiny in the infant-formula market. NAD decision on Kendamil infant formula claims Abbott Laboratories Stock Performance Shares of Abbott Laboratories stock opened at $108.86 on Wednesday. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company has a market cap of $188.37 billion, a PE ratio of 35.23, a P/E/G ratio of 2.05 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The business has a 50-day simple moving average of $103.43 and a 200-day simple moving average of $100.09.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter in the previous year, the business posted $1.26 EPS. The firm’s revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Abbott Laboratories Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

See Also Five stocks we like better than Abbott Laboratories Dutch Bros Sell-Off Creates a Growth Opportunity NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat Is Abercrombie & Fitch’s Hot Streak Just Getting Started? Medtronic’s Stars Are Aligning for a Price Recovery

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

E Fund Management Co. Ltd. bought a new position in shares of Abbott Laboratories (NYSE:ABT – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 9,773 shares of the healthcare product maker’s stock, valued at approximately $887,000.

Several other hedge funds and other institutional investors have also bought and sold shares of ABT. J. Stern & Co. LLP boosted its stake in Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after acquiring an additional 39,005,451 shares during the last quarter. Norges Bank purchased a new position in Abbott Laboratories in the fourth quarter valued at approximately $2,938,892,000. Flossbach Von Storch SE bought a new position in Abbott Laboratories during the second quarter valued at $902,938,000. BlackRock Inc. raised its stake in shares of Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock valued at $13,843,610,000 after buying an additional 6,769,518 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Abbott Laboratories by 217.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 5,522,222 shares of the healthcare product maker’s stock valued at $566,967,000 after buying an additional 3,780,402 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance ABT stock opened at $112.63 on Monday. The firm has a 50 day moving average of $102.61 and a 200-day moving average of $100.14. The firm has a market capitalization of $194.89 billion, a P/E ratio of 36.45, a price-to-earnings-growth ratio of 2.18 and a beta of 0.59. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the prior year, the company posted $1.26 EPS. The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year. Abbott Laboratories Dividend Announcement The firm also recently announced a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Trending Headlines about Abbott Laboratories Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott’s First Wearable Device for Dual Ketone and Glucose Tracking Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott’s next-generation Amulet 360 device receives CE Mark Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns. Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains Analyst Ratings Changes Several equities research analysts recently weighed in on ABT shares. The Goldman Sachs Group decreased their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Citigroup increased their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. JPMorgan Chase & Co. boosted their price target on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Bank of America dropped their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Finally, Weiss Ratings upgraded shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $119.50.

Check Out Our Latest Analysis on ABT

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Read More Five stocks we like better than Abbott Laboratories Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against? Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Advisors Capital Management LLC purchased a new position in Abbott Laboratories (NYSE:ABT – Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 48,015 shares of the healthcare product maker’s stock, valued at approximately $4,357,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. MidAtlantic Capital Management Inc. bought a new position in shares of Abbott Laboratories during the fourth quarter valued at approximately $25,000. Cornerstone Financial Management LLC acquired a new position in Abbott Laboratories during the 4th quarter valued at about $25,000. Purpose Unlimited Inc. acquired a new position in shares of Abbott Laboratories during the fourth quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. bought a new position in Abbott Laboratories during the 4th quarter valued at $26,000. Finally, Abound Financial LLC acquired a new position in shares of Abbott Laboratories in the 4th quarter worth approximately $26,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analysts Set New Price Targets A number of equities analysts recently weighed in on the company. JPMorgan Chase & Co. increased their price target on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Wells Fargo & Company raised their price target on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Robert W. Baird initiated coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price target on the stock. Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective on the stock in a report on Thursday, August 13th. Finally, TD Cowen boosted their target price on Abbott Laboratories from $115.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, August 25th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Get Our Latest Analysis on ABT Abbott Laboratories Stock Up 0.1% Shares of ABT stock opened at $112.63 on Monday. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The stock has a 50 day moving average of $102.61 and a 200-day moving average of $100.14. The firm has a market cap of $194.89 billion, a PE ratio of 36.45, a price-to-earnings-growth ratio of 2.18 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business’s revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement The business also recently declared a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.2%. Abbott Laboratories’s payout ratio is currently 81.55%.

Key Headlines Impacting Abbott Laboratories Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott’s First Wearable Device for Dual Ketone and Glucose Tracking Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott’s next-generation Amulet 360 device receives CE Mark Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns. Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Read More Five stocks we like better than Abbott Laboratories Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against? Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

New Similac 360 Total Care Made With Whole Milk combines creamy whole milk for a fat blend that more closely resembles the fats in breast milk and five immune-nourishing prebiotics to help support baby's natural defenses—making it Similac's closest formula to breast milk Abbott's liquid-only launch reflects growing parent interest in infant formulas made with whole milk while offering the convenience and reassurance that comes with commercially sterile, ready-to-feed formula Product is available at prices similar to the per-feeding cost of powdered Similac 360 Total Care and is available online and at major U.S. retailers , /PRNewswire/ -- Parents looking for an infant formula made with whole milk now have a new option. Abbott (NYSE: ABT) today announced the launch of Similac® 360 Total Care Made With Whole Milk—the first and only commercially sterile, ready-to-feed liquid infant formula made with whole milk in the United States. This new formula is available at launch pricing similar to the per-feeding cost of Similac 360 Total Care powdered infant formulas.

Similac 360 Total Care Made With Whole Milk Ready to Feed

Similac 360 Total Care Made With Whole Milk Ready to Feed

Similac 360 Total Care Made With Whole Milk Ready to Feed

Similac 360 Total Care Made With Whole Milk Ready to Feed

Similac 360 Total Care Made With Whole Milk Ready to Feed

Similac 360 Total Care Made With Whole Milk Ready to Feed Experience the full interactive Multichannel News Release here: https://www.multivu.com/abbott/9415851-en-abbott-launches-similac-360-total-care-made-with-whole-milk

Infant formulas made with whole milk have become a popular choice because they provide a fat blend that more closely resembles the fats found in breast milk. Similac 360 Total Care Made With Whole Milk is Similac's closest formula to breast milk. It combines whole milk and an exclusive blend of five human milk oligosaccharides (HMOs), which are prebiotics structurally identical to five of those found in breast milk. This formula is designed to help support a baby's immune system, brain development, and digestive health. Similac 360 Total Care Made With Whole Milk is also non-GMOi and does not contain artificial growth hormonesii, corn syrup or palm olein oil.

"Parents have been asking for more whole milk options, and we wanted to give them something they couldn't get anywhere else," said Misha Pardubicka-Jenkins, Abbott's U.S. vice president and general manager for pediatric nutrition. "We decided on a liquid-only approach to give families the benefits of whole milk, the convenience of a formula that's ready when baby is, and the reassurance that comes with a commercially sterile liquid formula. And through launch, we'll make it accessible to more families by offering it at powder-like prices."

Abbott made the decision to bring this new formula to American families in a commercially sterile, liquid offering only. This gives parents the choice of formula made with whole milk in a convenient, ready-to-feed format, and it provides the inherent peace of mind that comes with liquid infant formulas. Unlike powdered formula, ready-to-feed liquid formula requires no preparation. Parents can simply open and feed, whether at home, while traveling or during overnight feedings. Whether powder or liquid, parents can use all Similac formulas confidently.

"As a pediatrician, I've spent decades helping parents navigate infant feeding, so I know how meaningful it is to find a formula option parents feel confident choosing," said Karyn Wulf, M.D., pediatrician and senior medical director in Abbott's nutrition division. "All Similac formulas start with high-quality ingredients that provide the essential nutrition babies need to grow and develop. Ready-to-feed infant formulas offer parents convenience because they require no mixing and the reassurance that comes with a commercially sterile liquid."

Availability and pricing
Starting today, Similac 360 Total Care Made With Whole Milk is available at Target and Amazon. Over the coming weeks, customers can find the liquid formula at Walmart and additional retail and club locations, grocers and pharmacy chains.

While liquid infant formulas typically cost more than powdered, Abbott is launching the 8 fl oz and 32 fl oz sizes of Similac 360 Total Care Made With Whole Milk at prices similar to the per-feeding cost of Similac 360 Total Care powdered infant formulas. This gives more families access to the convenience of ready-to-feed formula at pricing similar to powder.

Similac 360 Total Care Made With Whole Milk joins Abbott's extensive portfolio of infant formulas and expands feeding options for families seeking a formula made with whole milk. Each batch of Similac 360 Total Care Made With Whole Milk will be produced at Abbott's own manufacturing facility in the U.S.

Frequently Asked Questions:
Is Abbott discontinuing its original Similac 360 Total Care liquid infant formula?
No. For parents who prefer the original Similac 360 Total Care formula, that product will remain in 2 fl oz and 8 fl oz ready-to-feed format. Nothing changes in our original Similac 360 Total Care powdered formulas, which will still be available at various sizes and price points.

What does it mean for an infant formula to be commercially sterile?
While all formulas, including powdered formulas, are manufactured to eliminate potentially harmful microorganisms, commercial sterility means a liquid infant formula has undergone an additional, carefully controlled, validated heat treatment process designed to eliminate spores of potentially harmful microorganisms, particularly Clostridium spores. The nutritional quality of all Abbott's liquid, ready-to-feed infant formulas is maintained throughout the heat treatment process. All of Abbott's liquid, ready-to-feed infant formulas are commercially sterile.

Why are liquid, ready-to-feed infant formulas considered a safer formula option for certain babies?
Ready-to-feed liquid formulas are often used for convenience, especially in those late-night hours when mixing formula is less than ideal. However, both FDA and CDC advise parents of infants under two months of age and those with weakened immune systems should also consider feeding a commercially sterile liquid formula for infants not receiving breast milk.

Are powdered infant formulas safe?
Yes. Parents can continue using Similac powdered infant formulas with confidence, knowing that we design our manufacturing processes to help prevent the presence and growth of potentially harmful bacteria across both liquid and powder formula production. All of Abbott's powdered infant formulas are manufactured under rigorous quality and safety controls and meet or exceed industry regulations for infant formula testing.

About Similac®
Similac has been feeding babies for more than 100 years. Backed by Abbott's science and research, Similac is committed to supporting parents with high-quality infant nutrition that meets a wide variety of babies' needs and parents' preferences. Connect with us at Similac.com and on Facebook, Instagram, YouTube and TikTok.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

i *Ingredients not genetically engineered

ii Milk ingredients are derived from milk of non-rbST-treated cows, which is not different from milk of rbST-treated cows.

SOURCE Abbott

Bank Hapoalim BM boosted its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 80.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,765 shares of the healthcare product maker’s stock after purchasing an additional 5,699 shares during the quarter. Bank Hapoalim BM’s holdings in Abbott Laboratories were worth $1,158,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Cornerstone Financial Management LLC purchased a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. MidAtlantic Capital Management Inc. purchased a new position in shares of Abbott Laboratories in the 4th quarter valued at about $25,000. Purpose Unlimited Inc. purchased a new position in shares of Abbott Laboratories in the 4th quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at about $26,000. Finally, Abound Financial LLC purchased a new stake in Abbott Laboratories during the fourth quarter worth about $26,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analyst Ratings Changes A number of research analysts have recently weighed in on the company. BTIG Research raised their price target on Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Royal Bank Of Canada reissued an “outperform” rating and set a $130.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. UBS Group reduced their price objective on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Weiss Ratings raised Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $119.50.

Get Our Latest Research Report on Abbott Laboratories Abbott Laboratories Price Performance Shares of Abbott Laboratories stock opened at $116.12 on Wednesday. The business’s fifty day moving average price is $101.15 and its 200 day moving average price is $100.09. The stock has a market capitalization of $200.94 billion, a P/E ratio of 37.58, a PEG ratio of 2.26 and a beta of 0.59. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter last year, the firm posted $1.26 EPS. The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend The firm also recently announced a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were paid a dividend of $0.63 per share. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Key Headlines Impacting Abbott Laboratories Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: The FDA authorized Abbott’s Libre Duo 10 Day, the first continuous monitor designed to track both glucose and ketone levels. The device could strengthen Abbott’s FreeStyle Libre ecosystem, help identify rising ketones before diabetic ketoacidosis emergencies, and support compatibility with automated insulin-delivery systems. Reuters article Positive Sentiment: TD Cowen raised its price target for ABT to $135 from $115 and maintained a “buy” rating. The upgrade signals confidence in Abbott’s growth prospects, particularly in continuous glucose monitoring and medical devices. Benzinga article Positive Sentiment: Medtronic’s MiniMed Flex insulin pump has begun shipping with an Abbott-made glucose sensor, expanding the potential distribution and application of Abbott’s sensor technology in automated insulin delivery. MedTech Dive article Neutral Sentiment: Recent comparisons portray Abbott as a relatively attractive healthcare and continuous glucose monitoring investment, citing valuation, liquidity and price-target upside. These assessments may support sentiment but do not represent new company operating results. Yahoo Finance article Negative Sentiment: Abbott agreed to pay $670 million to settle claims that its specialized premature-infant formulas contributed to necrotizing enterocolitis. The settlement removes some litigation uncertainty but highlights continuing legal and financial risks. Insider Monkey article Negative Sentiment: Diagnostics growth remains uneven: strong routine testing and 13% cancer-diagnostics growth are being partly offset by weaker respiratory testing demand. This could temper near-term revenue momentum. Yahoo Finance article (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Further Reading Five stocks we like better than Abbott Laboratories Pathward’s Credit Scare Tests Its Comeback Story Wiring the AI Boom: Rumble’s $13.7B Pivot StoneX: Too Far Too Fast? DICK’s Sporting Goods Faces Pain Now for a Bigger Prize Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

BlackRock Inc. increased its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 4.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 152,563,476 shares of the healthcare product maker’s stock after acquiring an additional 6,769,518 shares during the period. BlackRock Inc. owned approximately 8.82% of Abbott Laboratories worth $13,843,610,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. MidAtlantic Capital Management Inc. acquired a new position in Abbott Laboratories in the fourth quarter valued at approximately $25,000. Cornerstone Financial Management LLC acquired a new stake in Abbott Laboratories during the fourth quarter worth approximately $25,000. Purpose Unlimited Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in shares of Abbott Laboratories in the 4th quarter valued at $26,000. Finally, Abound Financial LLC acquired a new position in Abbott Laboratories in the fourth quarter valued at $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance ABT opened at $112.63 on Friday. The stock’s 50 day simple moving average is $102.61 and its 200 day simple moving average is $100.22. The stock has a market cap of $194.89 billion, a P/E ratio of 36.45, a P/E/G ratio of 2.16 and a beta of 0.59. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.Abbott Laboratories’s revenue was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year. Abbott Laboratories Dividend Announcement The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Trending Headlines about Abbott Laboratories Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott’s First Wearable Device for Dual Ketone and Glucose Tracking Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott’s next-generation Amulet 360 device receives CE Mark Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns. Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains Wall Street Analyst Weigh In Several analysts have recently weighed in on the company. Royal Bank Of Canada reissued an “outperform” rating and issued a $130.00 target price on shares of Abbott Laboratories in a report on Friday, July 17th. Weiss Ratings raised Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 6th. Bank of America lowered their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Robert W. Baird began coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price target for the company. Finally, Citigroup increased their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $119.50.

View Our Latest Report on ABT

Abbott Laboratories Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Featured Articles Five stocks we like better than Abbott Laboratories 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude? Okta Stock Surges 29%—Is $200 the Next Stop? Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Golden Reserve Retirement LLC grew its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 155.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,138 shares of the healthcare product maker’s stock after acquiring an additional 5,557 shares during the quarter. Golden Reserve Retirement LLC’s holdings in Abbott Laboratories were worth $829,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Freemont Management S.A. increased its position in shares of Abbott Laboratories by 197.2% in the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock valued at $1,341,000 after acquiring an additional 7,100 shares during the period. PFA Pension Forsikringsaktieselskab acquired a new stake in Abbott Laboratories during the 4th quarter worth about $116,580,000. Thrivent Financial for Lutherans grew its stake in Abbott Laboratories by 24.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after purchasing an additional 48,286 shares during the last quarter. Aureus Asset Management LLC raised its stake in shares of Abbott Laboratories by 25.0% in the first quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock worth $34,078,000 after purchasing an additional 66,422 shares during the last quarter. Finally, North Dakota State Investment Board acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth about $7,439,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Price Performance NYSE:ABT opened at $116.70 on Tuesday. The stock has a market capitalization of $201.94 billion, a PE ratio of 37.77, a price-to-earnings-growth ratio of 2.26 and a beta of 0.59. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The stock’s 50-day moving average price is $100.64 and its 200-day moving average price is $100.03.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the previous year, the business earned $1.26 earnings per share. The business’s revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year. Abbott Laboratories Announces Dividend The business also recently announced a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

Key Abbott Laboratories News Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: New diabetes-device opportunity: Medtronic has begun shipping its MiniMed Flex insulin pump, which uses an Abbott-made glucose sensor. The launch and accompanying marketing campaign could expand Abbott’s sensor presence in the growing diabetes-care market. MiniMed starts shipping new insulin pump with Abbott-made sensor Positive Sentiment: Underlying business remains diversified: Analyst commentary highlights Abbott’s established diagnostics, medical-device and nutrition franchises, along with long-term growth opportunities. Its latest reported quarter also exceeded consensus earnings and revenue estimates, with revenue up 13% year over year. Ken Griffin Just Loaded Up on AbbVie and Abbott Neutral Sentiment: Formula litigation clarity: Abbott agreed to pay approximately $670 million to resolve the Gill case and about 2,000 additional necrotizing-enterocolitis claims without admitting liability. The settlement is costly, but it removes uncertainty tied to a large jury award and provides greater visibility into remaining litigation exposure. How Investors Are Reacting To Abbott Laboratories US$670 Million NEC Settlement Neutral Sentiment: Investor comparisons are favorable but valuation-sensitive: Articles describe Abbott as a potential long-term healthcare and dividend investment, though comparisons with Envista, Intuitive Surgical, Thermo Fisher and Johnson & Johnson emphasize differing growth, recovery and valuation profiles. NVST or ABT: Which Is the Better Value Stock Right Now? Negative Sentiment: Diagnostics growth is uneven: Weaker respiratory-testing demand is offsetting healthy routine testing and approximately 13% growth in cancer diagnostics. This mix could moderate near-term Diagnostics momentum despite strength in higher-growth categories. Here’s What Is Shaping Abbott’s Diagnostics Growth Analyst Upgrades and Downgrades Several brokerages recently weighed in on ABT. TD Cowen reiterated a “buy” rating and issued a $115.00 price target on shares of Abbott Laboratories in a report on Friday, July 17th. Robert W. Baird assumed coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price objective on the stock. JPMorgan Chase & Co. increased their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price for the company in a research report on Thursday, August 13th. Finally, UBS Group lowered their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $118.67.

View Our Latest Stock Report on ABT

Abbott Laboratories Company Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Further Reading Five stocks we like better than Abbott Laboratories Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain Snowflake Could Be Headed for New Highs Despite Insider Selling MongoDB Is Surging—And the Next Catalyst Is Almost Here

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways Abbott's Rapid and Molecular Diagnostics sales fell 8% as respiratory virus testing declined. ABT's Cancer Diagnostics sales rose 13%, driven by mid-teens Cologuard growth and oncology gains. Respiratory testing variability may keep Abbott's quarterly Diagnostics growth uneven. Abbott Laboratories’ (ABT - Free Report) Diagnostics business continues to face some near-term variability from the seasonal nature of respiratory testing, even as its underlying routine-testing and cancer franchises remain healthy. In the second quarter of 2026, Rapid and Molecular Diagnostics sales declined 8% on a comparable basis, driven by the anticipated falloff in respiratory virus testing following a weaker-than-normal respiratory season. This creates a difficult mix dynamic because fluctuations in flu, COVID-19 and other respiratory testing volumes can meaningfully affect quarterly growth despite relatively stable demand elsewhere in the Diagnostics business.  

However, the Cancer Diagnostics arm helped offset the weakness in respiratory testing. The segment’s sales grew 13% in the second quarter, driven by mid-teens growth in Cologuard. Growth also came from new and repeat Cologuard users, along with contributions from precision oncology and international markets. Accordingly, Abbott’s Diagnostics outlook is increasingly supported by Cancer Diagnostics rather than respiratory testing.

Thus, even with solid routine laboratory demand and expanding oncology testing, the segment’s quarterly growth rate can remain uneven because the timing and severity of respiratory outbreaks are difficult to forecast.

Peer UpdateRespiratory testing remains a swing factor for QuidelOrtho’s (QDEL - Free Report) revenues, mix and cash conversion. For the first six months of 2026, respiratory products accounted for 9% of total revenues compared with 13% in the prior-year period, as weaker flu and COVID-19 demand weighed on results. Although second-quarter 2026 Point of Care revenues increased 16% year over year, management said respiratory positivity rates remained markedly below 2025 levels.

Softness in the molecular diagnostics business due to sluggish demand for respiratory disease tests has been weighing on the performance of the Danaher’s (DHR - Free Report) Diagnostics segment. Volume-based procurement and increased reimbursement changes in China are concerning as well. The segment’s core revenues declined 4% on a year-over-year basis in the first quarter of 2026. However, solid momentum in the clinical diagnostics businesses, led by growth in the Beckman Colter Diagnostics unit, has been buoying the segment. 

ABT Price PerformanceIn the past year, Abbott shares have plunged 11.6% compared with the industry’s 22.9% decline. 

Image Source: Zacks Investment Research

Expensive ValuationABT currently trades at a forward 12-month Price-to-Sales (P/S) of 3.81X compared with the industry’s median of 2.81X.

Image Source: Zacks Investment Research

ABT Stock Estimate TrendIn the past 30 days, ABT’s EPS estimate for 2026 has remained unchanged.

Image Source: Zacks Investment Research

ABT stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

D.A. Davidson & CO. trimmed its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 20.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 148,208 shares of the healthcare product maker’s stock after selling 38,578 shares during the quarter. D.A. Davidson & CO.’s holdings in Abbott Laboratories were worth $13,448,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of ABT. MidAtlantic Capital Management Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter worth $25,000. Cornerstone Financial Management LLC purchased a new stake in Abbott Laboratories during the 4th quarter valued at $25,000. Purpose Unlimited Inc. bought a new stake in Abbott Laboratories in the 4th quarter worth $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter valued at about $26,000. Finally, Abound Financial LLC bought a new position in shares of Abbott Laboratories during the fourth quarter valued at about $26,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories News Summary Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Abbott’s Instinct continuous glucose sensor is now commercially shipping in the U.S. integrated with MiniMed’s Flex automated insulin-delivery system. The partnership expands Abbott’s presence in diabetes technology and could support sensor adoption and recurring revenue. MiniMed Ships MiniMed Flex With Abbott’s Smallest Instinct Sensor Positive Sentiment: Abbott also entered a multiyear agreement with HealthTab to distribute its Afinion 2 point-of-care analyzers through NHS-linked pharmacies in the United Kingdom. The deal may broaden access to Abbott’s HbA1c and lipid-testing products, although financial details were not disclosed. HealthTab Enters Multi-Year Collaboration Agreement with Abbott Neutral Sentiment: Abbott agreed to pay approximately $670 million to resolve the Gill case and claims from roughly 2,000 individuals involving specialty formulas for premature infants. The settlement resolves a portion of the litigation, including the appeal of a prior $495 million verdict, reducing uncertainty and potentially avoiding additional legal costs. Abbott denied that its products cause necrotizing enterocolitis and said regulators and medical professionals consider the formulas safe and necessary. Abbott agrees to $670 million settlement of infant formula cases Negative Sentiment: The settlement represents a significant cash and earnings cost and does not resolve all potential litigation related to the infant formulas. Investors may continue to assess the scope of remaining claims and the effect on Abbott’s legal reserves and profitability. Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas Analyst Ratings Changes Several research firms recently issued reports on ABT. Royal Bank Of Canada reissued an “outperform” rating and issued a $130.00 target price on shares of Abbott Laboratories in a research note on Friday, July 17th. Robert W. Baird started coverage on Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price objective for the company. Piper Sandler reiterated an “overweight” rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Citigroup upped their target price on Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a report on Friday, July 17th. Finally, Weiss Ratings upgraded shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 6th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and an average target price of $118.67. Get Our Latest Analysis on Abbott Laboratories

Abbott Laboratories Stock Up 2.2% Shares of NYSE:ABT opened at $116.62 on Friday. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $201.80 billion, a price-to-earnings ratio of 37.74, a PEG ratio of 2.26 and a beta of 0.59. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The stock has a fifty day simple moving average of $100.08 and a two-hundred day simple moving average of $100.05.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter in the prior year, the company posted $1.26 earnings per share. The business’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement The company also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Abbott Laboratories Company Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

See Also Five stocks we like better than Abbott Laboratories 2 Biotech Stocks Shaping Up for Major Breakouts 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit? Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Agreements will resolve the Gill case and claims involving approximately 2,000 other individuals Abbott and the medical community stand by the safety of preterm infant formulas Regulators and medical professionals recognize that these products are safe and necessary, and there is no reliable scientific evidence that they cause necrotizing enterocolitis , /PRNewswire/ -- Abbott (NYSE: ABT) has reached agreements with three law firms to resolve the Gill case and claims involving approximately 2,000 other individuals relating to the company's specialty formulas for preterm infants.

In July 2024, a St. Louis jury awarded the plaintiff in the Gill case $495 million in damages. Abbott appealed the verdict to the Missouri Court of Appeals in December 2024, but the appeal was denied. Rather than continuing to appeal or paying approximately $600 million, representing the Gill judgment plus accrued interest to date, Abbott entered into agreements to resolve the Gill case as well as necrotizing enterocolitis (NEC) claims asserted on behalf of approximately 2,000 additional infants for an aggregate amount of approximately $670 million.

These agreements are a compromise of disputed claims and not in any way an admission of liability. Abbott stands by the safety of these products and the essential role they play in helping the medical community care for preterm infants. The Food and Drug Administration, National Institutes of Health, Centers for Disease Control and Prevention, American Academy of Pediatrics, NEC Society, neonatologists and other medical professionals recognize that these products are safe and necessary, and that there is no reliable scientific evidence that they cause NEC.

The agreements follow a series of favorable rulings for preterm formula manufacturers in federal and state courts, including victories in all three federal Multidistrict Litigation (MDL) bellwether cases. In July 2026, the U.S. Court of Appeals for the Seventh Circuit affirmed a pretrial judgment for Abbott in the first federal MDL bellwether case involving the company's preterm infant formulas. In June 2026, the Illinois Appellate Court reversed a $60 million verdict against Mead Johnson, finding that the trial court failed to properly apply the learned intermediary doctrine governing a manufacturer's duty to warn, a defense relevant in a substantial number of cases. In March 2026, a Florida state court, applying the learned intermediary doctrine, also dismissed claims involving preterm infant formula.

While Abbott remains confident in the safety of these products and the science supporting them, the company believes these agreements are in its best long-term interest and represent a constructive step toward substantially resolving the overall litigation.

Following these agreements, there are roughly 1,700 lawsuits pending in federal and state courts involving claims on behalf of approximately 12,700 individual infants. That population includes claims on behalf of individuals who named both Abbott and Mead Johnson without identifying which manufacturer's formula was administered, individuals diagnosed with NEC before receiving any formula, individuals who were never diagnosed with NEC, and individuals who appear in multiple lawsuits in different jurisdictions. Abbott continues to work to identify and eliminate such claims and others like them.

Frequently Asked Questions

What is NEC?
Necrotizing enterocolitis, or NEC, is an inflammatory intestinal disease, which typically affects premature infants. Challenges associated with prematurity – such as an underdeveloped intestinal tract and immature immune system – can combine to lead to NEC, which explains why infants born the most prematurely are at the highest risk of NEC. 

Does preterm infant formula cause NEC?
No. Numerous scientific papers and NEC authorities have made clear that preterm infant formula does not cause NEC. Indeed, a 100-page report authored by a blue-ribbon Working Group of 24 doctors and eight government officials organized by the Department of Health and Human Services explained that "[a]vailable evidence supports the hypothesis that it is the absence of human milk – rather than the exposure to formula – that is associated with an increase in the risk of NEC."

Earlier this year, the AAP confirmed that "[p]reterm infant formula is recommended when [mother's own milk] is not available and [pasteurized donor human milk] is either not available or the family declines use." Dr. Mark Corkins, division chief of pediatric gastroenterology at the University of Tennessee Health Science Center, said: "There is no evidence that the formulas cause NEC. That is why these court cases make no sense to the folks who understand the actual science."

What is preterm infant formula?
Preterm infant formulas are specialty formulas that are designed to meet the unique nutritional needs of preterm and low-birth-weight infants, who need more calories and nutrients than full-term infants to survive and thrive. Thus, these products differ from infant formulas for full-term infants that are sold in stores directly to parents and caregivers. For decades, Abbott has researched, developed and produced these specialized nutrition products, and today Abbott is one of only two companies in the U.S. providing these products. FDA regulates preterm infant formula and has not asked for changes or additions to the ingredients or label. Abbott complies with all applicable FDA regulations.

Is preterm infant formula part of the standard of care?
Yes. The AAP has explained that "[p]roviding special formula is a routine and necessary part of care of these preterm infants." Likewise, the NEC Society – a non-profit focused on eradicating NEC – explained that "[s]ometimes, formula is necessary and chosen by the baby's care team as the best available plan of care." Preterm formula is especially important because mothers of premature infants may have trouble expressing a sufficient supply of breast milk and donor human milk is not always available. In these situations, preterm infant formula is a critical option.

In a brief filed on Aug. 7, 2026, to the U.S. Supreme Court, the AAP, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, National Association of Pediatric Nurse Practitioners, Perinatal Research Society, Children's Hospitals Neonatal Consortium, and March of Dimes wrote: "Preterm infant formula is an indispensable component of neonatal medicine" and that "[t]he medical community universally regards preterm formula as an essential, life-saving component of neonatal care."

What have federal health authorities and the medical community said about preterm infant formula?
The FDA, CDC and NIH, the AAP, and the NEC Society agree that preterm infant formulas are a vital necessity in caring for premature infants and that feeding decisions should be made in neonatal intensive care units (NICUs), not in courtrooms.

In October 2024, the FDA, CDC and NIH said: "There is no conclusive evidence that preterm infant formula causes NEC." Instead, "[a]vailable evidence supports the hypothesis that it is the absence of human milk – rather than the exposure to formula – that is associated with an increase in the risk of NEC." These groups also said: "These formulas can be critical for premature infants for whom parental or donor milk is not an option, or where a supplement to parental or donor milk is necessary for the health of the infant."

In September 2024, the American Academy of Pediatrics said: "Specialty formulas and fortifiers provide an essential source of nutrition for premature infants. While breastmilk is preferred, it does not eliminate the risk of NEC, and there is not always enough supply from a parent or donors."

In July 2024, the American Academy of Pediatrics said: "Courtrooms are not the best place to determine clinical recommendations for the care of infants. Feeding decisions should be made by clinicians and families. These need to be individualized in the context of human milk availability, specific patient needs, and individual family preferences."

In July 2024, the NEC Society said: "Feeding decisions should be made in the NICU, not in courtrooms."

In April 2024, the NEC Society said: "In the ICU, feeding decisions are medical decisions. It is imperative for medical decisions to be made by those who practice medicine in partnership with patient-families. The medical team, in collaboration with patient-families, should decide how babies are fed in the ICU. These medical feeding decisions aim to protect against NEC while providing optimal nutrition for discharge and long-term health outcomes. Neonatal feeding decisions should be made at patients' bedsides, not in courtrooms."

Why does access to preterm infant formula matter?
About 1 in every 10 infants born in the U.S. is premature, per the CDC. But per the AAP: "there is not always enough [human milk] supply from a parent or donors" for premature infants. As Judge Rebecca R. Pallmeyer, the judge in the federal MDL has recognized, "[t]his means that cow's-milk-based formulas, including [Similac Special Care 24], will remain essential products until the production of human-milk formula is sufficient to eliminate any risk of shortfalls in all NICUs nationwide." And "[f]ormula is designed to serve as a replacement whenever donor milk or mother's milk is unavailable, so the product's utility is categorical, not marginal." To use the Court's analogy, it is a "lifeboat" product.

Is the medical community concerned about continued access to preterm infant formula?
Yes. As the AAP has said: "Feeding decisions should be made by clinicians and families," not litigants. When these decisions are taken from clinicians, physicians, medical organizations and policymakers have expressed concern about continued access to preterm infant nutrition products. These groups have warned of potential impact on availability if manufacturers cannot continue supplying them given the threat of unending litigation.

In a brief filed on Aug. 7, 2026, to the U.S. Supreme Court, the AAP, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, National Association of Pediatric Nurse Practitioners, Perinatal Research Society, Children's Hospitals Neonatal Consortium, and March of Dimes wrote: "The substantial verdicts already entered in other cases, together with the thousands of similar claims now pending, pose a grave threat to the preterm formula supply. Should that supply diminish or be withdrawn, neonatologists and pediatric clinicians would lose an essential instrument of care and with foreseeable consequences: increased infant mortality, impaired neurological development, and permanent degradation of the standard of care for the Nation's most vulnerable patients."

What is the learned intermediary doctrine?
In both Watson v. Mead Johnson (Ill. App. Ct. 2026) and Ennix v. Abbott (Fla. Cir. Ct. 2026), courts held that the learned intermediary doctrine applies to preterm formula used in the NICU. That doctrine provides that a manufacturer's duty is to communicate to doctors, not directly to the patient, because it recognizes that doctors – not manufacturers – are in the best position to evaluate risks and benefits and advise parents accordingly.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, and on LinkedIn, Facebook, Instagram, X and YouTube. 

SOURCE Abbott

Key Takeaways Abbott's EPD sales rose 8.7% comparably in Q2 2026, led by 10.7% growth in Key Emerging Markets. Healthcare access, aging populations and treatment needs are supporting demand for established therapies.Abbott is expanding its biosimilar pipeline to broaden EPD's portfolio and create growth opportunities. Abbott Laboratories’ (ABT - Free Report) Established Pharmaceuticals Division (“EPD”) continues to be a solid growth contributor, supported by its broad portfolio of branded generic medicines and strong commercial presence across emerging markets. 

In the second quarter of 2026, EPD sales increased 8.4% on a reported basis and 8.7% on a comparable basis. Key Emerging Markets delivered 10.7% comparable sales growth, driven by double-digit growth in several countries across Latin America and Asia Pacific. The strong performance highlights the benefits of EPD’s diversified geographic footprint and its ability to capitalize on growing healthcare demand across emerging markets.

The EPD business continues to benefit from favorable structural trends, including expanding access to healthcare, aging populations and increasing treatment needs for both acute and chronic conditions. These trends are expanding the addressable patient population and supporting sustained demand for established pharmaceutical therapies.

Meanwhile, Abbott is expanding its biosimilar pipeline, which should broaden EPD’s product portfolio and create additional growth opportunities across key markets. The combination of a broad product portfolio, expanding pipeline, strong brand equity and disciplined commercial execution positions EPD to sustain high-single-digit sales growth over the long term.

Peer UpdateBoston Scientific’s (BSX - Free Report) international operations continue to support its growth profile, benefiting from a broad geographic presence across developed and emerging markets. In the second quarter of 2026, operational sales increased 4.2% in EMEA, 11.2% in APAC and 16.2% in Latin America and Canada. 

Growth in APAC was particularly strong, with double-digit gains across Japan, China and Korea, supported by momentum in Interventional Cardiology, Electrophysiology and WATCHMAN. Looking ahead, continued expansion of the FARAPULSE ecosystem, OPAL mapping platform and WATCHMAN FLX Pro should strengthen the company’s presence and support further penetration across key international markets. 

Medtronic (MDT - Free Report) also maintains a significant international presence, supported by broad-based demand for its medical technologies across multiple therapeutic areas. In fiscal 2026, international revenues totaled $18.26 billion and increased 6.2% organically, outpacing the 5.4% organic growth recorded in the United States. 

International revenues maintained 6.2% organic growth in the fourth quarter, with Cardiovascular increasing 7.1%, Neuroscience growing 5.8% and Diabetes up 12.2%. Structural Heart also delivered stronger performance outside the United States, while Diabetes continued to benefit from product innovation and geographic expansion, including Simplera Sync and the EMEA launch of MiniMed Go Smart MDI with Simplera. 

ABT Price PerformanceIn the past year, Abbott shares have plunged 14.3% compared with the industry’s 22.7% decline. 

Image Source: Zacks Investment Research

ABT's ValuationABT currently trades at a forward 12-month Price-to-Sales (P/S) of 3.63X compared with the industry median of 2.81X.

Image Source: Zacks Investment Research

ABT Stock Estimate TrendIn the past 30 days, ABT’s EPS estimate for 2026 has moved north 0.2%.

Image Source: Zacks Investment Research

ABT stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways Abbott's Diagnostics sales rose 42.3% reported and 2.9% comparable in Q2 2026, led by routine testing.Cancer Diagnostics sales grew 13.3%, driven by Cologuard, precision oncology and international operations. ABT expects faster Cancer Diagnostics growth in the second half on screenings and newer tests. Abbott Laboratories’ (ABT - Free Report) Diagnostics business manufactures and markets diagnostic systems and tests. The segment is transitioning from a pandemic-driven profile to a broader portfolio supported by routine testing and oncology.

In the second quarter of 2026, Diagnostics sales increased 42.3% on a reported basis and 2.9% on a comparable basis. Core Laboratory sales grew 3.2% on a comparable basis, including 7.5% growth in the United States. Testing demand remained resilient across hospitals and other laboratories. Rapid and Molecular Diagnostics sales declined 8% as respiratory testing normalized. However, the company expects easier comparisons in China and sustained demand outside China to support an improved growth trajectory in the second half.

Following the March 2026 acquisition of Exact Sciences, Diagnostics now includes the Cancer Diagnostics business. Cancer Diagnostics sales grew 13.3%, driven by mid-teens growth in Cologuard and a colorectal cancer screening test, along with contributions from precision oncology and international operations. Abbott expects Cancer Diagnostics’ growth to accelerate in the second half. This growth is expected to benefit from care gap programs, repeat screenings, newer tests and increased international adoption. 

Peer UpdateDanaher Corporation (DHR - Free Report) Diagnostics segment continued to perform strong in the second quarter, with core revenues increasing 2% year over year. Clinical diagnostics revenues grew at a mid-single-digit rate, supported by solid performance at Beckman Coulter Diagnostics and high-single-digit growth at Leica Biosystems and Radiometer. Cepheid’s non-respiratory revenues increased at a low-double-digit rate, driven by strength in hospital-acquired infection and sexual-health assays, while lower seasonal infection rates continued to pressure respiratory testing revenues. In China, declines at Beckman began to moderate as pricing stabilized and volumes improved, easing some of the pressure from volume-based procurement and reimbursement changes. 

QuidelOrtho Corporation (QDEL - Free Report) continues to benefit from its focus on the diagnostics business, supported by healthy growth across several key areas during the second quarter. Labs revenues increased 4% as reported driven by strength in the core business, although slower sales in China related to changes in In Vitro Diagnostics pricing partially offset growth. Immunohematology revenues increased 1% with growth improving to 5% outside China. Meanwhile, Point of Care remained a notable growth driver, with revenues advancing 16%, including a 10% increase in Triage revenues, highlighting solid momentum across the company’s diagnostics portfolio.

ABT Price PerformanceIn the past year, Abbott shares have plunged 19.6% compared with the industry’s 25.9% decline. 

Image Source: Zacks Investment Research

Expensive ValuationABT currently trades at a forward 12-month Price-to-Sales (P/S) of 3.54X compared with the industry median of 2.81X.

Image Source: Zacks Investment Research

ABT Stock Estimate TrendIn the past 30 days, ABT’s EPS estimate for 2026 has moved north 0.2%.

Image Source: Zacks Investment Research

ABT stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Posted by Defense World Staff on Jul 26th, 2026

Bank of Nova Scotia lessened its holdings in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 16.8% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 259,747 shares of the healthcare product maker’s stock after selling 52,490 shares during the quarter. Bank of Nova Scotia’s holdings in Abbott Laboratories were worth $26,668,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in ABT. Dickmeyer Boyce Financial Management Inc. acquired a new stake in Abbott Laboratories during the first quarter valued at approximately $829,000. Ascension Capital Advisors Inc. acquired a new position in shares of Abbott Laboratories in the 1st quarter worth approximately $459,000. Forefront Analytics LLC increased its holdings in shares of Abbott Laboratories by 34.3% in the 1st quarter. Forefront Analytics LLC now owns 5,043 shares of the healthcare product maker’s stock valued at $518,000 after acquiring an additional 1,287 shares during the last quarter. B&D White Capital Company LLC bought a new stake in shares of Abbott Laboratories in the 1st quarter valued at approximately $2,413,000. Finally, Cetera Investment Advisers raised its position in shares of Abbott Laboratories by 0.7% during the 1st quarter. Cetera Investment Advisers now owns 613,310 shares of the healthcare product maker’s stock valued at $62,968,000 after acquiring an additional 4,030 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets A number of equities analysts have commented on the stock. The Goldman Sachs Group decreased their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Stifel Nicolaus reduced their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Sanford C. Bernstein decreased their price target on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Bank of America lowered their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Finally, BTIG Research increased their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.61.

Read Our Latest Stock Analysis on Abbott Laboratories

Insiders Place Their Bets In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of the business’s stock in a transaction on Monday, April 27th. The shares were purchased at an average price of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 0.46% of the stock is owned by insiders.

Abbott Laboratories Trading Up 2.4% Shares of NYSE:ABT opened at $103.13 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The company’s 50-day moving average price is $91.61 and its 200 day moving average price is $101.33. The company has a market cap of $179.63 billion, a PE ratio of 33.38, a P/E/G ratio of 2.00 and a beta of 0.61. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The firm had revenue of $12.51 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter in the prior year, the firm earned $1.26 EPS. Abbott Laboratories’s quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.4%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Abbott Laboratories Company Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

See Also Five stocks we like better than Abbott Laboratories Telecom Earnings Reveal a Sector That Finally Looks Healthier Defense Earnings Show Readiness Now and Modernization Ahead Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off MarketBeat Week in Review – 07/20- 07/24 Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBank of Nova Scotia Buys New Stake in BWX Technologies, Inc. $BWXT

NEXT HEADLINE »Electronic Arts Inc. $EA Shares Sold by Assetmark Inc.

Key Takeaways ISRG is favored for its expanding robotic surgery ecosystem and stronger long-term growth outlook.Intuitive Surgical grew procedures, expanded its installed base and advanced da Vinci 5, SP and Ion.Abbott posted broad-based growth across devices, diagnostics, diabetes care and nutrition. Despite sharp declines in 2026, Intuitive Surgical (ISRG - Free Report) and Abbott Laboratories (ABT - Free Report) remain among the highest-quality names in MedTech. ISRG has declined 32.1% year to date, while ABT is down 20.1%, though both continue to execute well in their core businesses.

Intuitive Surgical’s growth is being fueled by the expanding adoption of its robotic surgery ecosystem, including da Vinci 5, SP and Ion platforms, while Abbott is benefiting from balanced momentum across cardiovascular devices, diagnostics, diabetes care and nutrition.

Looking ahead, both companies expect growth to continue through 2026, although Intuitive Surgical’s expanding robotic surgery franchise and innovation pipeline position it for stronger long-term upside.

YTD Price Chart ISRG vs ABT

Image Source: Zacks Investment Research

Case for ISRGIntuitive Surgical continues to widen its competitive moat by building a comprehensive robotic-assisted surgery ecosystem rather than relying on a single platform. During the second quarter, total procedures increased 16%, supported by 15% growth in da Vinci procedures and an impressive 36% increase in Ion procedures.

Adoption remained strong across da Vinci 5, single-port (SP) systems and Ion, while the company expanded its installed base to nearly 13,000 systems globally. Continued upgrades to da Vinci 5, broader adoption of XiR in ambulatory surgery centers and cost-sensitive international markets, and ongoing investments in AI-enabled workflow, simulation and telepresence reinforce management's long-term growth strategy.

Growth opportunities extend well beyond traditional robotic surgery. SP procedures surged 61%, Ion procedures surpassed 400,000 cumulatively, and management continues to invest in new disease areas such as gastrointestinal robotics, cardiac surgery and nipple-sparing mastectomy. Programs designed to reduce customer costs, including the upcoming EndoWrist extended-use initiative, should further expand adoption across outpatient procedures and international markets.

The company also faces several challenges, including slower U.S. elective procedure growth tied to changing patient coverage dynamics, competitive pressure in China, GLP-1-related weakness in bariatric surgery and higher R&D spending. Nevertheless, Intuitive Surgical continues to guide toward healthy procedure growth for 2026 while investing aggressively to extend its technology leadership.

ISRG’s Sales & EPS Growth Estimate

Image Source: Zacks Investment Research

Case for ABTAbbott's growth strategy is built on diversification across multiple healthcare markets rather than dependence on any single business. Medical Devices remained a key contributor in the second quarter, with 8.5% growth driven by electrophysiology, rhythm management, heart failure and continuous glucose monitoring. Management expects growth to accelerate further as Volt 2.0, TactiFlex Duo, Libre Duo, Amulet 360 and several cardiovascular products are commercialized over the coming year. Strong momentum in diagnostics, emerging-market pharmaceuticals and improving nutrition performance also support ABT’s balanced growth outlook.

Abbott's broad portfolio provides resilience, but it also means growth is spread across numerous franchises rather than being driven by a single transformational platform. While continuous glucose monitoring remains a significant long-term opportunity, management acknowledged that reimbursement expansion timing remains difficult to predict.

Cancer diagnostics, core laboratory testing and electrophysiology are expected to drive second-half acceleration, while nutrition continues recovering steadily. Risks include declining respiratory testing volumes, reimbursement uncertainties for diabetes products and the need to execute multiple product launches successfully to sustain projected acceleration. Overall, Abbott's diversified model provides stability but offers a less concentrated growth story than Intuitive Surgical's robotics franchise.

ABT’s Sales & EPS Growth Estimate

Image Source: Zacks Investment Research

Valuation ComparisonDespite a steep fall in its valuation since the beginning of 2025, ISRG trades at a premium, supported by sustained double-digit growth, expanding global adoption, and a long runway in minimally invasive surgery. Its performance demonstrates resilience despite external pressures, such as tariffs. The company currently trades at a forward 12-month P/E multiple of 30.55, above the industry average of 24.41, and carries a Value Score of D.

ISRG’s P/E F12M Chart

Image Source: Zacks Investment Research

ABT offers a more balanced risk profile, with dependable earnings growth and margin expansion driven by operational discipline. Its upside potential appears comparatively constrained, given its mature and diversified business mix. The company currently trades at P/E F12M ratio of 17.33X, slightly above the industry average of 16.02X. ABT carries a Value Score of C.

ABT’s P/E F12M Chart

Image Source: Zacks Investment Research

ConclusionBoth companies possess durable competitive advantages and robust innovation pipelines. Abbott offers investors diversified exposure across diagnostics, cardiovascular devices, diabetes care and nutrition, helping reduce reliance on any single market. Intuitive Surgical stands out for its leadership in robotic-assisted surgery, expanding clinical indications, accelerating adoption of da Vinci 5, SP and Ion, and sustained investment in next-generation technologies. Although ISRG trades at a premium valuation, its stronger innovation pipeline, faster-growing robotic ecosystem and Zacks Rank #2 (Buy) make it a more compelling long-term MedTech investment than Abbott, which carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

AlTi Global Inc. lowered its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 54.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,563 shares of the healthcare product maker’s stock after selling 12,779 shares during the period. AlTi Global Inc.’s holdings in Abbott Laboratories were worth $1,085,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in shares of Abbott Laboratories by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after buying an additional 2,402,408 shares in the last quarter. State Street Corp lifted its stake in Abbott Laboratories by 2.1% in the 4th quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock worth $10,004,880,000 after purchasing an additional 1,627,791 shares in the last quarter. Capital International Investors boosted its holdings in shares of Abbott Laboratories by 2.6% during the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock worth $7,922,519,000 after purchasing an additional 1,614,706 shares during the last quarter. J. Stern & Co. LLP grew its position in shares of Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares in the last quarter. Finally, Capital Research Global Investors increased its holdings in shares of Abbott Laboratories by 1.0% in the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock valued at $4,907,523,000 after purchasing an additional 400,400 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes A number of equities analysts have weighed in on the company. Daiwa Securities Group lowered Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective on the stock. in a research note on Wednesday, April 22nd. Robert W. Baird started coverage on Abbott Laboratories in a report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price target on the stock. Weiss Ratings raised shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, July 7th. Citigroup upped their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a report on Friday. Finally, Sanford C. Bernstein reduced their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $118.61.

Read Our Latest Report on Abbott Laboratories

Insiders Place Their Bets In other news, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average price of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Philip P. Boudreau bought 2,200 shares of the company’s stock in a transaction on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Stock Up 1.0% Shares of ABT opened at $101.72 on Tuesday. The company’s 50-day moving average price is $90.28 and its 200 day moving average price is $101.84. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The firm has a market cap of $177.18 billion, a P/E ratio of 32.92, a price-to-earnings-growth ratio of 1.73 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. The company had revenue of $12.51 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. Abbott Laboratories’s revenue was up 13.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. Abbott Laboratories’s payout ratio is presently 81.55%.

Abbott Laboratories Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Featured Articles Five stocks we like better than Abbott Laboratories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.